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ABSTRACT 
Polycyclic aromatic hydrocarbons (P AHs) are common environmental pollutants 
resulting from incomplete combustion of organic matter, emission sources, automobile 
exhausts, cigarette smoke (CS), residential wood, or coal combustion. PAHs are readily 
absorbed from the gastrointestinal tract of mammals and have toxic, mutagenic and/or 
carcinogenic consequences. More than 100 different P AH compounds are identified. 
Sixteen of the common P AHs typically analyzed have been listed by the Environmental 
Protection Agency (EPA) among 129 priority pollutants, and five of which are listed 
among the 25 hazardous substances that are believed to have the most potential threat to 
human health at priority superfund sites. 
CS has been implicated as a major risk factor in atherosclerotic heart disease 
through a mechanism that involves endothelial cell (EC) injury and apoptosis or 
programmed cell death. Little is known about the specific components of CS responsible 
for this effect or the mechanisms by which CS induces EC injury and progression of 
atherosclerosis. However, the phospholipase A2/arachidonic acid (PLA2/ AA) pathway 
might be involved in SC-induced EC injury. 
In this research, the long-range goal was to understand the role of several P AHs 
found in the environment and CS in the EC and smooth muscle cells (SMC) injury. The 
hypothesis to be tested is that EC and SMC PAR-induced apoptosis is mediated by 
PLAi/ AA pathway. 
The objectives of this research were 1) to evaluate the effects on EC injury of 
different P AHs present in high concentration in both Chattanooga creek and CS. 2) to 
test the molecular mechanisms by which P AHs induce such effect. 3) to test the effect of 
IV 
P AHs on SMC in vitro and to characterize the role of different PLA2 isoforms in such 
effect. 
In this research, we found that Chattanooga creek contains extremely high levels 
of 11 out of 16 EPA priority P AHs. The levels range from 10,625 mg/kg soil 
(phenanthrene) to 97 mg/kg soil for fluorene compounds. Six out of the 11 compounds 
studied, found in the creek or in CS, activate the AA cascade and induce apoptosis of EC. 
Three of the 11 P AHs cause these effects by activating and increasing the expression of 
two different isoforms of PLA2; the Group VI� and the Group IVy enzymes. 
Furthermore, three out of 11 activate and increase expression of only the Group IVy 
PLA2. PLA2 activation and release of AA is associated with an increase in apoptosis as 
measured by histone fragmentation and cleavage of P ARP. From these results, we 
hypothesize that the water solubility as well as the molecular structures of the compounds 
play important roles in the effects of P AHs on EC PLA2 activation and apoptosis. These 
data suggest that small molecular weight, highly water soluble compounds present in 
high concentrations in the Chattanooga creek and CS may be potentially toxic confirming 
the need for further studies. 
We also found that 8 P AHs present in high concentrations in CS and in urban 
pollution induce EC apoptosis by a mechanism that involves PLA2-mediated activation of 
JNK.s, p-38, and caspases-8, -9, and -3. PAHs induce phosphorylation of JNK-1, JNK-2, 
p-38, and the transcription factor c-Jun, resulting in apoptosis in EC. This effect is 
inhibited significantly by MAPP (Group IV and VI PLA2 inhibitor) and JNK-1 L form 
(JNK-1 and -2 inhibitor) but not with SB203580 (p-38 inhibitor). These data provide 
compelling evidence that P AHs induce apoptosis by a mechanism that involves fatty 
V 
acid-induced phosphorylation of JNK-1 and JNK-2. Furthermore, p-38 phosphorylation 
did not participate in the mechanism by which P AHs induce apoptosis. This study also 
establishes a link between the discrete structure of these P AHs and their activity. 
We investigated the effect of 8 different P AHs on SMC PLA2 activation and 
induction of apoptosis. Our data show that five of the 8 compounds tested cause 3H-AA 
release in a concentration-dependent fashion. The 5 active compounds also induce apoptosis 
at a concentration that induce significant 3H-AA release. In addition, specific PLA2 
inhibitors that are selective for Group IV and VI enzymes inhibit 3H-AA release and 
attenuate the apoptotic effect, suggesting that P AHs induce SMC apoptosis by a mechanism 
thati nvolves PLA2. Results from cell-free PLA2 activity assays, RT-PCR, and Western 
blotting show that SMC express 4 isoforms of PLA2, Group IV a, J3, y, and Group VIJ3 PLA2. 
Transfection of SMC with PLA2 isoforms that were the most strongly expressed (Group IV-y 
and Group VIJ3) causes a significant increase in 3H-AA when stimulated with active P AHs as 
compared to wild type cells. Our data suggest that both of these enzymes are responsible for 
PAR-induced AA release and subsequent apoptosis in SMC with the possibility of Group 
IV a and J3 involvement in this effect. 
This study demonstrates the involvement of P AHs in EC and for the first time in 
SMC. Furthermore, our data suggest that small molecular weight, highly water-soluble 
compounds present in Chattanooga creek may be potentially toxic confirming the need for 
further studies. 
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PART I: Introduction 
1 
BACKGROUND AND SIGNIFICANCE 
Polycyclic aromatic hydrocarbons and atherosclerosis 
Polycyclic aromatic hydrocarbons (P AHs) are an important class of environmental 
xenobiotics that are abundant in the environment and in food. They are formed by 
incomplete combustion of organic matter. They also come from automobile exhaust, 
tobacco smoke, residential wood, and coal combustion 1•2 . P AHs are highly lipophilic 
and, thus readily absorbed from the gastrointestinal tract of mammals. Many studies 
indicate that P AHs have toxic, mutagenic and/or carcinogenic consequence3 •4• There are 
more than 100 different P AH compounds that are identified. Sixteen of the common 
P AHs typically analyzed have been listed by the Environmental Protection Agency 
(EPA) among 129 priority pollutants. Five of those compounds are listed among the 25 
hazardous substances that are believed to have the most potential threat to human health 
at priority superfund sites5'6 • 
P AHs are classified into two groups depending upon their physical and chemical 
properties. Low-molecular-weight P AHs, contain three or fewer aromatic rings and high­
molecular-weight P AHs, contain more than three aromatic rings3•7•8 • Alkyl and chlorine 
substitutions may exist on one or more rings. Those substitutions change the fate and 
effect of P AHs often making them more toxic3 '8 • P AHs can also be grouped into 
different categories depending on their molecular weight, number of rings present and 
water solubility7'8 . Table 1 shows different chemical and physical properties for the 
P AHs used in this study7 • P AHs are likely to partition into sediments and soils, with 
relatively small concentrations of many PAHs showing up in water due to low solubility. 
It has been shown that two-ring compounds are more soluble than heavier three-ring 
2 
compounds, and thus might be more toxic3•8• However, recent studies have shown that 
some of the heavier P AHs can exhibit acute water toxicity at levels below solubilities due 
to photo-enhanced toxicity in the presence of ultraviolet (UV) or other types of solar 
radiation3• 7•8 • 
Previous studies of structure-activity relationships of P AHs, have focused mainly 
on the genotoxic and tumor-initiating properties of these compounds9• Discrete structural 
determinants are required for these effects. It was reported previously that the potent 
genetic toxicity of two- to four-ringed P AHs requires a bay- or a bay-like region in the 
molecule. Linear PAHs that do not contain these regions are not genotoxic9• The 
existence of a discrete structural determinant for activity suggests that these compounds 
interact with a protein or proteins in the cell. Whether a ligand binds to a protein can 
depend on the size of the ligand. A large molecule may be too bulky to bind the active 
site of the protein, whereas a smaller molecule can. Thus, it is likely that both molecular 
structure and solubility play important roles in the toxic effects of P AHs 7•10•11• 
P AHs, cigarette smoke and disease 
Cigarette smoke (CS) has been implicated as a major risk factor in pulmonary diseases 
such as chronic bronchitis, emphysema, carcinogenesis, and atherosclerotic heart 
disease12-14• CS contains more than 4,000 constituents including reactive oxygen species, 
such as superoxide and hydroxyl radicals3, P AHs, cadmium, carbon monoxide, and 
nicotine15• P AHs present in the highest concentrations in CS include methylated 
anthracenes (1500 ng/cigarette), substituted and unsubstituted naphthalenes (276 
ng/cigarette), acenapthylene (64 ng/cigarette), acenaphthene (46.8 ng./cigarette), 
3 
phenanthrene ( 1 19 ng/cigarette), substituted and unsubstituted fluorenes ( 19 1  ng/ 
cigarette), fluoranthene (41 ng/cigarette), and pyrene (PY; 35.4 ng/cigarette)3• 16• 
The augmentation of atherosclerosis by CS involves endothelial cell (EC) injury 
as smokers demonstrate an increase in EC death and loss into the circulation when 
compared to non-smokers17• Several studies have indicated that CS induces EC injury by 
apoptosis or programmed cell death 1 8 • Wang and his colleagues showed that CS induced 
EC apoptosis, in a dose dependant-manner, that was mediated by transcription factors and 
caspase-3 1 8 • Little is known, however, about the specific components of CS responsible 
for this effect. 
EC injury and phospholipase A2 enzymes 
The results of recent epidemiologic studies suggest that EC injury associated with 
myocardial infarction may involve the phospholipase A2 (PLA2)/arachidonic acid (AA) 
pathway (PLA2/AA)19• Consumption of diets high in fish has been shown to reduce by 
50% the risk of death due to coronary artery disease in smokers 13 . Fish intake protects 
against the deleterious effects of smoking due to the presence of ro-3 fatty acids in fish 
oils, which act by altering the AA cascade20• Furthermore, inhibition of AA metabolism 
by administration of nonsteroidal antiinflammatory drugs decreases significantly the 
incidence of coronary heart disease in smokers2 1 • These results suggest that alterations in 
AA metabolism caused by smoking are important in the pathogenesis of smoking­
induced atherosclerosis. 
We recently demonstrated that P AHs present in CS in high concentration 
stimulate PLA2-mediated release of membrane fatty acids, PLA2 activation and EC 
apoptosis, suggesting the involvement of P AHs in the progression of atherosclerosis22 • 
4 
The family of PLA�s 
PLA2s comprise a broad and diverse family of enzymes that exhibit different substrate 
specificities, cofactor requirements, subcellular localization, and cellular functions23,24. 
PLA2s hydrolyze membrane phospholipids at the sn-2 position, and release many lipid 
products that are important either for housekeeping functions such as membrane 
remodeling, or for the production of inflammatory lipid mediators e.g. AA or other fatty 
acids25. AA, which is a second messenger, also serves as a substrate for the generation of 
eicosanoids25. Eicosanoids are known to be potent inflammatory lipid mediators that are 
generated from AA through cyclooxygenase, lipoxygenase, and cytochrome P-450 
enzymes23. 
Several systems have been used to classify PLA2s26. In general, mammalian 
PLA2s are classified into three major groups, calcium-dependent secretory (sPLA2), 
calcium-dependent cytosolic ( cPLA2), and calcium- independent cytosolic (iPLA2)23-25. 
PLA2s are also classified according to whether their active site contains a serine or a 
histidine residue24. In general, small molecular weight secreted isofonns (Groups I, II, 
III, V, IX, and X) have a histidine at the active site; whereas the large molecular weight 
intracellular enzymes (Groups IV and VI) have an active site serine. Of the Groups IV 
and VI enzymes, several isofonns have been identified23-26. Table 2 summarizes the 
general properties of different mammalian PLA2 isofonns23-26. 
PLA2 isoforms and apoptosis 
Several studies have reported the involvement of groups IV a PLA2 and VIJ3 PLA2 in 
apoptotic signal transduction pathways22,24,27-3 1 • Past reports indicate that Group IV a is 
involved in tumor necrosis factor-a (TNF-a) -induced apoptosis and that cells from 
5 
knock-out mice are resistant to the effects of TNF-a.3 1 • However, Fas/Fas L has been 
shown to be equally effective in mediating apoptosis in Group IV a. positive and negative 
cell lines27 • Upon activation by H2O2 in smooth muscle cell (SMC), IV a. releases AA 
that in turn causes phosphorylation of proapoptotic proteins such as; c-Jun and c-fos24• 
Previous studies have also implicated Group VIP in apoptotic cell death caused by 
the Fas/Fas-associated death domain (FADD) pathway22•32 . Interaction of Fas with its 
ligand activates Group VIP and causes release of fatty acids that induce phosphorylation 
of stress-activated protein kinases (SAPK) such as c-jun-N-terminal kinases (JNK.s) and 
p38. These kinases cause downstream activation of transcription factors and caspases. 
Moreover, there is a positive feedback loop identified, wherein fatty acid-induced caspase 
activation causes reciprocal VIP cleavage. The cleaved product exhibits a 2- to 3-fold 
increase in PLA2 activity, thus further driving the process of apoptosis
32
• An earlier study 
indicates that activation of PLA2 by oxidized LDLs contained within atherosclerotic 
plaques results in the release of AA and subsequent activation of SAPK/JNK.s33 • These 
enzymes, of which 4 isoforms have been characterized (JNK.-1, JNK.-2 JNK.-3 and p-38), 
phosphorylate and activate transcription factors such as c-Jun and transcription factor 
activator protein- I (AP-1 ), which play important roles in regulation of cell growth and 
apoptosis 16 • The apoptotic pathway regulated by JNKs involves activation of caspases 8 
and 9 that subsequently activate caspase-3 1 8 • Apoptotic stimuli generate signals that are 
either transmitted across the plasma membrane to intracellular regulatory molecules or 
directly target proapoptotic molecules inside the cells. An example of the former 
mechanism is the Fas/FasL/FADD pathway. Binding ofFasL to Fas recruits the death 
6 
domain protein, F ADD, which is required for caspase-8 activation and subsequent 
initiation of lethal proteolytic cascades. F ADD couples the Fas death receptor to 
procaspase-8, and subsequent oligomerization promotes procaspase-8 autoactivation34•35 • 
The latter mechanism involves the regulation of mitochondrial function by the Bcl-2 
family of proteins. Release of cytochrome c from the mitochondria is a proapoptotic 
signal. Proapoptotic protease activating factor (Apaf-1) is activated upon binding with 
cytochrome c after its release from the mitochondria. The antiapoptotic Bcl-2 proteins 
downregulate apoptosis by either prevention of cytochrome c release directly, or by 
sequestering Apaf-136. There is also a reciprocal regulation ofBcl-2 by cytochrome c. 
Apoptotic signals can block Bcl-2 function, which in turn causes mitochondrial 
membrane depolarization and subsequent cytochrome c release, proteolytic activation of 
procaspase-9, and subsequent activation of caspase-3 and other lethal proteolytic 
cascades36• 
Vascular smooth muscle apoptosis and atherosclerosis 
EC are not the only cells that undergo apoptosis during atherosclerosis. There is 
compelling evidence that apoptosis of SMC is also important in atherosclerosis 16• SMC 
play an important role in the maintenance of atherosclerotic fibrous plaque strength since 
they produce interstitial collagen that provides plaque tensile strength 16• During 
atherosclerosis SMC become activated and migrate into the intima to proliferate and 
produce extracellular matrix proteins37• SMC produce collagen that plays an important 
role in the maintenance of plaque tensile strength 16• Recent studies provide convincing 
evidence that SMC apoptosis is an important mechanism of SMC loss, reduction of 
7 
plaque tensile strength, and subsequent plaque rupture during atherosclerosis and acute 
myocardial infarction38 • 
HYPOTHESES AND OBJECTIVES 
The central hypothesis of this research is that P AHs selectively induce vascular cell (EC 
and SMC) injury by a mechanism mediated by PLA2 enzymes. 
The first objective of this study was to test the hypothesis that P AHs present in 
the environment induce EC injury by a mechanism that involves PLAi-mediated release 
of AA. For this purpose the Chattanooga creek sediments were surveyed for the presence 
of EPA priority P AHs, and the 11 P AHs present in the highest concentrations were 
evaluated for their effects on EC PLA2 activation and apoptosis. 
P AHs have also been shown by others to activate JNK.s and p-38; however 
upstream signal transduction mechanisms have not been determined18 • Since oxidized 
LDLs have been shown to be involved in EC apoptosis by a mechanism that involves AA 
and JNK., it is possible that PAHs act in a similar fashion 19• For that reason, the second 
objective of this study was to test the hypothesis that P AHs induce EC apoptosis by a 
mechanism that involves PLAi-mediated activation of JNK.s, p-38 and caspases -8, -9, 
and -3. For this purpose, the effects of 8 P AHs were investigated. 
Since SMC loss/injury is known to be important in the process of coronary artery 
disease and atherosclerotic disease involving other arteries as we1137•38, induction of SMC 
apoptosis by cigarette components may represent an important mechanism of smoking­
induced augmentation of cardiovascular diseases. The third objective of this study is to 
investigate the effects of 9 PAHs on SMC in vitro and tq characterize the roles of 
8 
different PLA2 isoforms in this effect. In addition, we intend to investigate the effects of 
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APPENDIX 
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Table 1. Chemical and physical properties of P AHs 
1 
PAHs Structure Molecular weight Water solubility 
mg/L 
Anthracene CCX) 178.24 0.075 
Anthr1ccnc 
1 20-1 2-7 
2-Methylanthracene CCXY�. 192.26 0.039 
2-methylanthr=e 
6 1 3- 12-7 
1-Methylanthracene OX) 192.3 0.261 
1-m ethylan thraccne 
6 1 0-48--0 
1-Methylfluorene o=o�· 180.25 1.092 
1 -m eth y l fl u o re n e  






Fluorene ::XO 166.23 1.90 
Fluorene 
8 6 -7 3 -7 
Fluoranthene o£ 202.26 0.24 
f lu o r 1 n th c n c  
2 0 6 -4 4 -0 
Phenantherene o9 178.24 1.65 
P hc11a 11tbrc11e 
S S -0 1 -8 
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202.26 0. 165 
228.3 0.00 1 5  
2 1 6.29 0.002 
1 8  
Table 2. Mammalian phospholipase A2 Groups 
Size Ca:2+ Substrate 
Group Sources (kD) requirements specificity 
IP Porcine/human 1 3 - 1 5  MM None
a 
II Human/rodents 1 3- 1 7  MM None 
IVa Human/rat 85 <µM AA 
IVP Human 1 14 <µM None 
IVy Human 6 1  None None 
V All 14  MM None 
Via Human 40 None AA 
vm Human 85-88 None None 
VII Human/mouse/porcine 40-45 None None 
VIII Human 26 None None 
X Human/mouse 14  MM None 
a It will cleave AA and other fatty acids from the membrane phospholipids. 
b p-bromophenacyl bromide (non-specific sPLA2 inhibitor). 
c Arachidonyl trifluoromethyl ketone (a potent cPLA2 inhibitor). 













PART II: Environmental pollutants activate phospholipase A2 isoforms 
and induce apoptosis of human coronary artery endothelial cells 
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INTRODUCTION 
Several major cities in Tennessee have significant levels of industrial pollution, including 
Knoxville, Memphis, Nashville, and Chattanooga. South Chattanooga is an old industrial 
area where industrial pollutants are found in vapors, aerosols, solutes, particulates, liquids 
and sludges. Since 1917, coal carbonization byproducts were discharged into a 2.5 mile 
section of the Chattanooga creek. A Health Advisory was issued by the Agency for 
Toxic Substances and Disease Registry concerning human contact with coal tar deposits 
in South Chattanooga in 1993 1 •2• After U.S. Environmental Protection Agency (EPA) 
study in 1994, the creek was placed on the National Priorities List and South Chattanooga 
was designated as a Superfund site due to excessive accumulation of industrial pollutants 
in the air, soil and water. The EPA removed coal-tar deposits and contaminated 
sediments from a one-mile section of Chattanooga creek in 1997 and 1998; however, no 
remediation has been conducted on the adjacent floodplain2• Moreover, little information 
is available concerning the potential health risks to inhabitants of South Chattanooga. 
Exposure to industrial pollutants increases the incidence of several diseases 
including cancer, pulmonary and cardiovascular diseases3 • Atherosclerosis and 
subsequent heart disease is the leading cause of death in the United States. Recent 
epidemiologic studies show a po�itive correlation between levels of particulate air 
pollution and daily morbidity and mortality due to acute myocardial infarction in major 
cities in the United States3• Another major risk factor for the development of 
atherosclerotic vascular disease is cigarette smoking (CS)4. Important toxic constituents 
that CS and urban pollution have in common are the polycyclic aromatic hydrocarbons 
(P AHs )3•4. Several P AHs have been shown to promote atherosclerosis in animal models; 
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however, the exact pathophysiological mechanisms have not been determined5•6• It is 
likely that endothelial cells (EC) injury plays a role since this is the earliest and most 
critical event in the development of atherosclerosis. Indeed, it is well known that the 
augmentation of atherosclerosis by CS involves EC injury since smokers demonstrate an 
increase in EC death and loss into the circulation when compared to non-smokers 7• 
Numerous studies have demonstrated that cells die in atherosclerotic plaques 
through apoptosis8•9• Apoptosis is characterized by cellular events that include cellular 
shrinkage, nuclear condensation, membrane blebbing, and apoptotic body phagocytosis8• 
Biochemical alterations also occur during apoptosis including alterations in gene 
expression and activation of endonucleases that induce DNA fragmentation8 • A role for 
the phospholipase A2 (PLA2)/arachidonic acid (AA) pathway in apoptosis is emerging
10-
t4 
PLA2s comprise a large and diverse family of enzymes that exhibit different 
substrate specificities, cofactor requirements, subcellular localizations, and cellular 
functions. PLA2s hydrolyze membrane phospholipids at the sn-2 position and release AA 
or other fatty acids that are important in the production of over 100 biologically active 
lipid mediators13 • PLA2, AA and many of its metabolites induce apoptosis by activating 
pathways such as c-Jun-N-terminal kinases (JNK.s) and sphingomyelinases that are 
involved in this process1 3 • 
We have demonstrated recently that three P AHs present in high concentration in 
CS induce apoptosis of human coronary artery EC (HCAEC) by a mechanism that 
involves activation of three different isoforms of PLA2 • 1-methylanthracene, a three-ring 
P AH induces apoptosis by activating a Group VI calcium-independent enzyme; whereas 
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benzo(a)pyrene exerts this effect by activating a Group IV PLA2 • In contrast, 
phenanthrene induces apoptosis by a mechanism that involves two isoforms of PLA2, a 
Group VI enzyme and the lysosomal, acidic, calcium-independent PLA2 (aiPLA2)1 4 . 
The purpose of the present study was to test the hypothesis that P AHs present in 
the environment induce EC injury by a mechanism that involves PLArmediated release 
of AA. For this purpose the Chattanooga creek sediments were surveyed for the presence 
of 16  EPA ·priority P AHs and the P AHs present in the highest concentrations were 
evaluated for their effects on EC PLA2 activation and apoptosis. 
MATERIALS AND METHODS 
Materials 
All PAHs were obtained from Aldrich (Milwaukee, WI). [5,6,8,9,1 1 ,12,14,15-3H] 
arachidonic acid (3H-AA; 200-240 Ci/mmol) was purchased from American 
Radio labeled Chemicals (St. Louis, MO). Bromoenol lactone (BEL) and 
methylarachidonoyl fluorophosphonate (MAFP) were obtained from Biomol (Plymouth 
Meeting, PA). Anti-P ARP antibody was obtained from Pharmingen (San Jose, CA). 
Cell death elisa plus apoptosis kit was obtained from Roche (Indianapolis, IN). The 
antibody to Group VI iPLA2 was obtained from Upstate Biotechnology (Lake Placid, 
NY) and the antibody to Group IVy was produced as described previously 1 5• 
Methods 
Creek sediment sample extractions for P AH. 
All creek bottom sediment samples were collected along Chattanooga creek and stored 
immediately under dry ice. These samples were transferred to a -80 °C freezer in the 
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laboratory until hot solvent extractions were performed. Soil extraction for P AHs was 
performed using a commercially available Accelerated Solvent Extractor (ASE 300, 
Dionex Corp., Sunnyvale, CA). The extraction protocols and quality control procedures 
followed were according to EPA SW-846 Method 3545A (pressurized fluid extraction) 
and Method 8270D (semivolatile organic compounds by GC/MS). A 10 g (wet weight) 
of sediment sample was thoroughly mixed with 10 g of Hydromatrix (inert diatomaceous 
earth, Varian Inc.,Palo Alto, CA). Each sample was extracted at 100 °C with methylene 
chloride and acetone (1:1, v/v) at a pressure of 1500 psi for a total time of 20 min. A 
surrogate spike mixture was added to each sample before the extraction procedure to 
measure extraction efficiency. Method blanks and laboratory controls were carried out 
using the same extraction protocol but with uncontaminated background soil collected 
from Ooltewah, TN {Tupelo series soil). All sample extracts were concentrated to a final 
volume of 2 ml (in an amber vial) and stored at -20 ° C pending further analyses. 
Sample extracts were analyzed using a Hewlett Packard gas chromatograph (GC, Model 
6890) equipped with Mass Selective Detector (MSD, Model 5973) and a HP auto 
sampler. Helium was used as the carrier gas, and a constant flow rate (0.6 mVmin) was 
maintained by electronic pressure control. A DB-5MS column (30 m x 0.25 mm i.d., 
J&W Scientific, Folsom, CA) was used for separating PAH compounds in the GC 
according to EPA Method 8270D. An internal standard mixture was added into each GC 
sample before the analysis. The concentration of each of the 16 EPA priority P AH 
compounds in the sediment samples were quantified based on analysis of a P AH standard 
mixture containing the 16 P AH compounds. The concentration of each of the 16 P AH 
compounds was calculated using the following equation: 
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A A 
cone. = std.cone. x � x _L 
A1s Axs 
where std. cone. is the concentration of the P AH compound in the standard mixture, A1ss 
is the area of the internal standard peak present in the P AH standard, A1s is the area of the 
samples internal standard peak, Ax is the area of the P AH compound peak within the 
sample analysis, Axs is the area of the compound peak in the P AH standard mixture, and 
cone. is the concentration of the P AH compound in the sample. 
Cell culture 
HCAEC were obtained from Clonetics (San Diego, CA) and were maintained in 
microvascular EC growth media (Clonetics, San Diego, CA) containing 5% fetal bovine 
serum. The cells were maintained at 37 °C in an atmosphere of 5% CO2/95% 02 • 
PLA2 activity/ AA release 
HCAEC were seeded into 6-well plates ( 1 05 cells/well) in growth medium. At 75 % 
confluence, cells were prelabeled for 24 hrs with 0.25 µCi/ml of 3H-arachidonic acid {3H­
AA). The cells at 80-90% confluency were washed twice with Hanks' balanced salt 
solution (HBSS) and equilibrated for 45 min in HBSS + 0. 1 % bovine serum albumin 
(BSA). BSA was used to inhibit reacylation and metabolism of released 3H-AA thus the 
data reflect cumulative release of 3H-AA. Radio labeled cells were exposed to various 
concentrations of P AHs present in the highest concentrations in the contaminated section 
of the Chattanooga creek. These included 1 -methylanthracene ( 1 -MA), 2-
methylanthracene (2-MA), anthracene (AN), fluorene (FL), 1 -methylfluorene ( 1-MF), 2-
methylfluorene (2-MF), phenanthrene (PA), fluoranthene (FA), chrysene (CH), 
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benzo[k]fluoranthene (B[k]F), and pyrene, (PY) (Figure 1 1). Cells were exposed to 
P AHs or vehicle for 60 min and cumulative release of 3H-AA into the medium was 
measured by scintillation counting and expressed as percent of total cellular radioactivity. 
To determine the PLA2 isoforms activated by various P AHs, 3H-AA release was 
measured in stimulated HCAEC in the presence and absence of bromoenol lactone [BEL; 
inhibitor of Group VI iPLA2] 14, and methylarachidonoyl fluorophosphonate [MAFP; 
inhibitor Groups IV and VI PLA2s] 14• 
Apoptosis 
Two methods were used to measure apoptosis caused by P AHs: Western analysis for the 
cleavage product of poly-ADP-ribose polymerase (P ARP) and ELISA for detection of 
histone fragmentation. 
P ARP cleavage was determined after treatment with PAHs or vehicle (DMSO) 
for 6 hrs. Crude extracts of protein were prepared by suspending in ice-cold sample 
buffer (62.5% Tris-HCL, pH 6.8, 6 M urea, 1 0% glycerol, 2% SDS, 0.003% 
bromophenol blue, 5% �-mercaptoethanol) containing protease inhibitors. Cells were 
lysed by sonication on ice for 2 XlO  s, 40% duty and lysates (40 µg of protein) subjected 
to 8 % SDS-polyacrylamide gel electrophoresis. The proteins in the gel were transferred 
to nitrocellulose membranes via a semi-dry blotting apparatus, the membrane blocked in 
5% nonfat dry milk in phosphate buffer saline (PBS)/0.1 % Tween 20, and incubated 
overnight at 4 °C with an anti-PARP antibody. Visualization was enhanced by 
chemiluminescence (ECL) (Amersham Pharmacia Biotech). 
1 See all figures and tables in appendix 
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Apoptosis was also evaluated fluorimetrically utilizing the Cell death elisa plus kit 
for detecting histone fragmentation. Cells seeded into 6-well plates were treated at 80-
90% confluency with 30 µM P AHs or vehicle for 3 hrs. Histone fragmentation was 
evaluated in cells treated with all eight P AHs in the presence and absence of the PLA2 
inhibitor MAFP .. Cells were then washed with warm PBS, lysed and incubated with 
antihistone-biotin and anti-DNA-POD at room temperature for 2 hrs. After washing with 
incubation buffer, 100 µ1 of substrate solution was added to develop the color and 
measurements made at 405 nm using a plate reader. Additional preliminary experiments 
were performed to ensure that neither the P AHs nor the inhibitors interfered with this 
fluorescent assay. 
Cell-free PLA2 activity 
To verify results obtained with intact cells, cell free PLA2 activity was measured in whole 
cell sonicates as described previously 16• Cells were washed in Ca2+-free PBS containing 
5 mM EDT A and 1 mM PMSF, resuspended in cold homogenizing buffer, placed on ice, 
and sonicated. Light microscopy was used to verify that the cells were broken. Based on 
previous inhibitor studies, experiments were designed to assay for Groups IV a, p, y and 
VIJ3 enzymes. Since Groups IVa and IVy prefer AA over linoleic acid at the sn-2 
position, the substrate l -palmitoyl-2- [arachidonoyl-1 -14C] phosphatidylcholine (14C-AA­
PC) was used to assay for their activities. Since Groups IVP and VIP are arachidonoyl­
nonselective, the substrate 1 -palmitoyl-2-linoleoyl [linoleoyl-1 -14C] phosphatidylcholine 
( 14C-LA-PC) was used to assay for their activities. Substrates were dried under nitrogen 
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and resuspended by sonication in assay buffer to a final optimum concentration as 
determined in preliminary experiments. 
To determine the role of calcium in activation of PLA2, assays were performed in 
the presence of either 5 mM CaCh or 5 mM EGT A. To determine if P AHs activate PLA2 
enzymes by interacting directly with the proteins, cell lysates were incubated with 14C­
AA-PC or 14C-LA-PC for 30 minutes in the presence and absence of PAHs. Experiments 
were also performed in the presence and absence of inhibitors (MAFP and BEL) to 
validate the selectivity of inhibitors for specific isoforms. Cell-free PLA2 assays are 
designed to target selected isoforms and therefore, are an effective means to validate the 
specificity of inhibitors for select PLA2 isoforms. Reactions were terminated by addition 
of chloroform-methanol, 2: 1 (v/v); the chloroform layer extracted and spotted on silica 
gel thin layer chromatography plates. The plates were chromatographed in a neutral lipid 
solvent and the lipids visualized with Ii vapor. The zones corresponding to fatty acid and 
phospholipid were cut out and radioactivity determined by scintillation counting. 
Western analysis of PLA2 isoforms 
To determine if PAHs upregulate PLA2 isoforms, cells were treated with four active 
compounds (1-MA, PA, FA, 1-MF), 1 inactive compound (AN) or vehicle for 4 hours 
and Western blotting performed with cell lysates. After treatment the cells were washed 
with PBS and then lysed in RIP A buffer (50mM Tris, 1 50 mM NaCl, 1 % SDS, 0.5% 
sodium deoxycholate, 1 mM DTI, 100 µM p-4-(2-aminoethyl)-benzenesulfonyl fluoride, 
1 µM pepstatin, and 1 00 µM leupeptin). The lysate was centrifuged at 1 0,000 g for 20 
min and the supernatant subjected to 1 0% SDS-polyacrylamide gel electrophoresis and 
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transferred onto nitrocellulose membranes. The membranes were probed with antibodies 
against Group VIJ3 PLA2 and. Group IVy PLA2• Bands were visualized by enhanced 
ECL. 
Statistical analysis 
Data are expressed as mean ± SEM. Data were analyzed by analysis of variance, and 
group means were compared using Student-Newman-Keuls'. Appropriate 
transformations were performed on all data that did not follow a normal distribution ( e.g. 
percent data). In addition, when variances are not equal or if transformation failed to 
normalize the data, nonparametric statistics (Mann-Whitney rank sum test) were used. 
For all studies, the criterion for statistical significance was p<0.05. 
RESULTS 
P AH levels found in contaminated and uncontaminated sediment from Chattanooga 
creek 
The P AH levels measured in the Chattanooga creek bed are shown in Table 1. Very low 
or non-detectable levels of P AHs were found in the uncontaminated reference area; 
however, extremely high levels were observed in the portion of the creek considered to 
be contaminated. These levels ranged from 10,625 mg/kg soil (phenanthrene) to 97 
mg/kg soil for fluorene compounds (Table 1 ). These compounds were used to evaluate 
potential toxicity of P AHs found in the Chattanooga creek. Eleven P AHs found in the 
highest concentrations in the creek were evaluated for their ability to activate PLA2s and 
induce apoptosis. 
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P AH-induced PLA� activation and 3H-AA release 
Little 3H-AA release was observed from unstimulated HCAEC or from cells exposed to 
AN and 2-MA; however, 1-MA, caused significant, concentration-dependent release of 
3H-AA (Figure 2A). FA and PA induced significant 3H-AA release; however, the 
responses to CH, PY, and B[k]F were not different from vehicle-treated control (Figure 
2B). However, FL and its methylated derivatives all caused concentration-dependent 3H­
AA release (Figure 2C). Pretreatment with MAFP, an inhibitor of Group IV and VI 
PLA2 isoforms, attenuated significantly the release of 3H-AA from cells treated with 1-
MA, 1-MF, 2-MF, FL, FA, and PA (Figure 3). However, BEL, the inhibitor of Group VI 
enzymes, attenuated only the response to 1-MA, FA, and PA (Figure 4). 
PAR-induced apoptosis 
All six compounds that caused 3H-AA release also induced apoptosis as determined by 
histone fragmentation ( 1-MA, 1-MF, FL, 2-MF, FA, and PA); however, the compounds 
that failed to induce 3H-AA release also failed to induce apoptosis (AN, 2-MA, CH, 
B[k]F, and PY (Figure SA).  To verify the results with histone fragmentation, Western 
analysis for the cleavage product of PARP was evaluated for active, and 2 inactive 
compounds (Figure SB). 1-MA, 1 -MF, 2-MF, FL, FA, and PA, compounds that activated 
PLA2, also induced apoptosis. The two compounds, AN and 1-MA, that did not cause 
3H-AA release, also did not induce apoptosis. 
Inhibition of apoptosis by MAFP 
To investigate whether PLA2 activation is required for P AH-induced apoptosis, histone 
fragmentation was determined in the presence and absence of the PLA2 inhibitor, MAFP. 
Apoptosis induced by all six compounds was significantly inhibited by MAFP (Figure 6). 
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Histone fragmentation experiments were not performed with BEL because it also 
functions as a protease inhibitor and as a consequence would inhibit caspases and 
apoptosis due to effects unrelated to PLA2 inhibition. 
Cell-free PLA7 assays 
To characterize further the PLA2 isoforms functioning in HCAEC, cell-free assays were 
performed. As can be seen in Figure 7 A, when 14C-AA-PC was used as a substrate to 
assay for Group IV enzymes, PLA2 activity was significantly greater than blank (DMSO, 
no protein) and MAFP, but not BEL, attenuated that response. Activity was also not 
significantly different in the presence and absence of calcium. Furthermore, treatment of 
lysates with active P AHs did not enhance PLA2 activity (Figure 7B). When 14C-LA-PC 
was used as a substrate, there was significant PLA2 activity under calcium-free conditions 
and this activity was inhibited significantly by both MAPP and BEL (Figure 8A). 
Treatment of lysates with active P AHs failed to cause a change in activity (Figure 8B). 
P AH-induced expression of PLA� isoforms 
The results of the cell-free assays suggested that the predominant activity in HCAEC was 
due to the Group VIJ3 (this enzyme prefers linoleic acid at the sn-2 position, is calcium­
independent and inhibited by BEL and MAPP) and the Group IVy (this enzyme prefers 
AA, is calcium-independent and inhibited only by MAPP). Therefore, experiments were 
performed to evaluate whether incubation with P AHs would result in upregulation of 
these two isoforms. Treatment for 4 hours with 1-MA, PA, and FA, but not vehicle, I ­
MF, or AN caused a significant increase in expression of the Group VIJ3 enzyme; 
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whereas the Group IVy enzyme was significantly upregulated by all active compounds 
(PA, FA, 1 -MF, and 1 -MA) but not an inactive compound (AN) or vehicle (Figure 9). 
DISCUSSION 
This study confirms that significant levels of P AHs are present in the Chattanooga creek 
as a result of industrial contamination. Moreover, 6 of the 1 1  compounds were toxic to 
EC at low micromolar concentrations. They induced 3H-AA release in a concentration­
dependent manner, and this event preceded the onset of apoptosis. Inhibition of fatty acid 
release with selective PLA2 inhibitors significantly attenuated P AH-induced apoptosis. 
These data confirm previous studies and provide compelling evidence that P AHs cause 
EC death by a mechanism that involves PLAi-induced release of fatty acids from the sn-2 
position of membrane phospholipids. 
Of the three anthracene compounds, only 1 -MA caused release of 3H-AA and 
apoptosis. 2-MA and AN caused neither effect. Since there are no major differences in 
water solubility between these compounds, the data are suggestive of a discrete structural 
determinant necessary for activation of PLA2 and subsequent apoptosis. The major 
differences between 1 -MA, 2-MA, and AN are that 1 -MA is a compound that contains a 
bay-like region on the molecule, whereas 2-MA and AN are linear compounds (Figure 1 ). 
These results are consistent with previous studies by others that have demonstrated that 
bay- and bay-like regions are required for P AH-induced activation of c-jun-N-terminal 
kinase 17• The results with CH and B[k]F; however, inconsistent with this hypothesis 
since these compounds have bay regions but were inactive. One possibility for this is that 
these compounds are significantly bulkier than the other active compounds with bay or 
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bay-like regions. The existence of a discrete structural determinant for activity suggests 
that these compounds interact with a protein or proteins in the cell. Whether a ligand 
binds to a protein can depend on the size of the ligand. A large molecule may be too 
bulky to bind the active site of the protein, whereas a smaller molecule can. Another 
possible explanation for these results is that CH and B[k]F are significantly less water 
soluble (0.002 mg/L and 0.0008 mg/L, respectively) than the active compounds FA (0.26 
mg/L) and PA (1 .6 mg/L). However, solubility cannot explain all the results. If so, it 
would be expected that a direct relationship would exist between water solubility and 
PLA2 activation and this was not the case. For example, FA was significantly more 
active than PA in activating PLA2 and inducing apoptosis, but it was an order of 
magnitude less soluble than PA. Thus, it is likely that both molecular structure and 
solubility play important roles in the effects of P AHs on EC PLA2 activation and 
apoptosis 1 8-20• 
The results of this study suggest that the three active compounds with bay- or bay­
like regions (PA, 1 -MA, and FA) activated two isoforms of PLA2 • MAFP is an inhibitor 
of Group IV enzymes, IV a, � and y. PLA2 IV a is an 85 kD enzyme that is arachidonoyl­
selective and dependent on calcium for phosphorylation and activation. Group IV� is an 
114  kD arachidonoyl-nonselective enzyme that is also calcium-dependentu ·2 1 • In 
contrast, Group IVy is a 61 kD protein that lacks the calcium-binding domains of the 
other two isoforms12•22•23 • Results from cell-free PLA2 assays provide strong evidence 
that the Group IV isoform targeted by PA, 1 -MA, and FA is IVy. Evidence for this 
conclusion is provided by the fact that addition of calcium to the assay buffer did not 
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cause an increase in PLA2 activity. Moreover, only MAFP inhibited this effect. The lack 
of inhibition by BEL rules out the possibility that this assay was measuring Group VI 
enzymes. In addition, W estem blotting after longterm exposure to PA, 1-MA, or FA 
caused significant induction of Group IVy expression. 
The data suggest that these three P AHs also activate Group VIP PLA2 and this 
effect is also responsible for apoptosis of EC. The group VI inhibitor, BEL, also caused 
inhibition of 3H-AA release and apoptosis of EC after treatment with PA, 1-MA or FA. 
In addition, long-term exposure to the three P AHs caused a significant increase in 
expression of the Group VIP enzyme. However, BEL was significantly less efficacious 
than MAFP in inhibiting PLA2 activity and apoptosis, suggesting a lesser role for the 
Group VI enzyme in the effects of these P AHs. 
All three fluorene compounds activated PLA2 and induced apoptosis. PLA2 
activation, AA release and apoptosis were inhibited significantly by MAFP, but not BEL. 
Also, a representative compound, 1-MF, increased expression of the Group IVy enzyme, 
but not the Group VIP enzyme. These data suggest that fluorene compounds induce 
apoptosis by activating Group IVy. 
When cell lysates were exposed to active P AHs and cell free PLA2 activity 
measured, no differences were seen in Group IVy or VIP activity when compared to 
vehicle control. These data provide strong evidence that P AHs do not act by directly 
interacting with PLA2 enzymes and provide support for the activation of upstream 
signaling proteins. Many of the compounds studied bind the aryl hydrocarbon receptor, 
albeit with low affinity24 and activation of this receptor has been shown to induce 
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apoptosis25. The possibility that these compounds bind other, as yet, unidentified 
-receptors that are involved in activation of PLA2 also cannot be excluded. Indeed, a 4 s 
PAH-binding protein has been identified and is now known to be glycine N-methyl­
transferase26, thus indicating the potential for these compounds to bind and alter the 
activity of more than one protein in the cell. Fas/Fas Ligand-induced apoptosis involves 
the activation of Group VIP 10; therefore, it is possible that the three P AHs that caused 
apoptosis by a mechanism that involved that enzyme activated the Fas pathway. 
PLA2 activation by P AHs may also be related to the ability of these compounds to 
induce oxidative stress. It is well known that oxygen radicals are produced during the 
cellular metabolism of PAHs27. Moreover, both the Group VI and the Group IVP 
enzymes are activated by oxidative stress, and oxygen radicals like hydrogen peroxide 
can induce apoptosis ofEC22. 
Another plausible mechanism for the effects of P AHs on PLA2 activity is, 
because of their lipophilicity, they may be able to enhance the interaction of the PLA2 
enzymes with their substrates. For example, the Group VI enzyme is ~80 kD in size, but 
the target size of the catalytically active enzyme is 337 +/- 25 kD, indicating that it exists 
as a large oligomeric coinplex28. P AHs may facilitate the assembly of this complex thus 
causing an increase in the activity of the enzyme. Indeed, other lipophilic compounds 
have been shown to facilitate assembly of protein complexes. One example of this is the 
NADPH oxidase enzyme that is responsible for the production of superoxide anion2 1 ·22. 
This enzyme exists in its active form as a complex of several proteins and cofactors. AA, 
because of its _ lipophilicity, induces a conformation that is required to achieve proper 
assembly of the protein complex22. The question of whether P AHs activate PLA2 
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isofonns by inducing oxidative stress, enhancing phospholipid/enzyme interactions or by 
interacting with signaling proteins is the subject of future investigations. 
Less information is available about the means by which exposure to particulate air 
pollution causes heart disease; however, the mechanism by which CS induces heart 
disease is better understood. Since CS contains many of the toxicants present in urban 
pollution, studies examining the pathophysiology of smoking-induced heart disease can 
be extrapolated to the effects of urban pollution. A 20 year prospective study provided 
compelling evidence for a link between activation of the PLA2/ AA cascade and heart 
disease in smokers. The Honolulu Heart Project initiated in 1 968 followed a cohort of 
8006 Japanese-American men aged 45 to 65 years of age. The results of this study 
demonstrated clearly that mortality and morbidity due to coronary heart disease was 
significantly less (50%) in heavy smokers who consumed diets high in ro-3 fatty acids4, 
compounds known to inhibit the AA pathway at several different levels29. The same 
protection was not observed in non-smokers4• This study, in addition to others5,30, 
suggests that components of CS activate this cascade. Since EC loss/injury is known to 
be important in the process of coronary artery disease and atherosclerotic disease 
involving other arteries as well, induction of endothelial cell apoptosis by cigarette 
components may represent an important mechanism of smoking-induced augmentation of 
cardiovascular diseases. Identification of specific structural requirements for PLA2 
activation and subsequent EC apoptosis may provide information about the potential 
toxicities of PAH compounds found in CS as well as in the environment. This 
information may prove to be useful in risk assessment and in discovery of effective 
preventative and therapeutic strategies in patients at risk for heart disease. 
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SUMMARY 
Our results show that Chattanooga creek contains extremely high levels of 11 out of 16 EPA 
priority PAHs. The levels ranged from 10,625 mg/kg soil (phenanthrene) to 97 mg/kg soil 
for fluorene compounds. Six out of the 11 compounds studied, found in the creek or in CS, 
activate the AA cascade and induce apoptosis of EC. Three of the 11 P AHs cause these 
effects by activating and increasing the expression of two different isoforms of PLA2; the 
Group VIP and the Group IVy enzymes. Furthermore, three out of 11 activated and increase 
expression of only the Group IVy PLA2• PLA2 activation and release of AA was associated 
with an increase in apoptosis as measured by histone fragmentation and cleavage of P ARP. 
From these results, we hypothesize that the water solubility as well as the molecular 
structures of the compounds play important roles in the effects of PAHs on EC PLA2 
activation and apoptosis. These data suggest that small molecular weight; highly water­
soluble compounds present in high concentrations in the Chattanooga creek and CS may be 
potentially toxic confirming the need for further studies. 
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Figure 1. Structures of polycyclic aromatic hydrocarbons. Antrhracene (AN), 2-
methylanthracene (2-MA), and pyrene (PY) are linear structures. 1 -metheylanthracene 
(1 -MA), and 1 -methylfluorene (1 -MF) have bay-like region formed by methyl group. 
Fluorene (FL), 2-methylfluorene (2-MF), fluoranthene (FA), chrysene (CH), 
benzo[k]fluoranthene (B [k]F), and phenantherene (PA) have bay-region. 
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Table 1 .  Polycyclic Aromatic Hydrocarbons Detected in Sediment From Chattanooga 
Creek 
Polycyclic Aromatic Background (mg/kg soil) Contaminated (mg/kg 
Hydrocarbons soil) 
Anthracenes ND 2622 
Pyrene 8 67 1 1  
Benzo[k ]fluoranthene ND 1 023 
Chrysene 1 2088 
Fluoranthene 8 8563 
Fluorenes ND 97 
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Figure 2. 3H-arachidonic acid (3H-AA) release from human coronary artery endothelial 
cells. Figure 2 A shows 3H-AA release induced by 1 -methylanthracene (1 -MA), but not 
by anthracene (AN) or 2-methylanthracene (2-MA). Cells were prelabeled with 3H-AA 
and stimulated for 1 hour with vehicle or various concentrations of 1 -MA, AN, or 2-MA 
as described in Materials and Methods. Cumulative release of 3H-AA into the medium 
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Figure 2. Continued. Figure 2 B shows 3H-arachidonic acid (3H-AA) release from human 
coronary artery endothelial cells induced by fluoranthene (FA) and phenanthrene (PA), 
but not chrysene (CH), pyrene (PY), or benzo[k]fluoranthene (B[k]F). Cells were 
prelabeled with 3H-AA and stimulated for 1 hour with various concentrations of FA, PA, 
CS, PY, B[k]F, or vehicle as described in Materials and Methods. Cumulative release of 
3H..;AA into the medium was measured by scintillation counting. * Significantly different 
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Figure 2. Continued. Figure 2 C shows 3H-arachidonic acid {3H-AA) release from human 
coronary artery endothelial cells induced by fluorene fL), 1 -methylfluorene (1 -MF), and 
2-methylfluorene (2-MF). Cells were prelabeled with H-AA and stimulated for 1 hour 
with various concentrations of FL, 1 -MF, 2-MF, or vehicle as described in Materials and 
Methods. Cumulative release of 3H-AA into the medium was measured by scintillation 








Figure 3. Inhibition of PAR-induced 3H-AA release from human coronary artery 
endothelial cells by methylarachidonoyl fluorophosphonate (MAFP). Cells prelabeled 
with 3H-AA were pretreated with 1 0  µM MAFP or vehicle for 30 min and stimulated 
with 30 µM 1 -MA, FL, 1 -MN, 2-MN, FA, PA, or vehicle for 1 hr. Release of 3H-AA into 
the medium was measured as described in Materials and Methods. * Significantly 
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Figure 4. Inhibition of PAR-induced 3H-AA release from human coronary artery 
endothelial cells by bromoenol lactone (BEL). Cells prelabeled with 3H-AA were 
pretreated with 7.5 µM BEL or vehicle for 30 min and stimulated with 30 µM 1 -MA, FL, 
1-MN, 2-MN, FA, PA, or vehicle for 1 hr. Release of 3H-AA into the medium was 
measured as described in Materials and Methods. *Significantly different from response 
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Figure 5. Apoptosis of human coronary artery endothelial cells induced by P AHs. Figure 
5 A shows histone fragmentation for cells treated with 30 µM 1-MA, AN, 2-MA, FL, I ­
MF, 2-MF, FA, PA, CH, B[k]F, PY, or vehicle for 2 hr and apoptosis determined by 
detection ofhistone fragmentation as described in Materials and Methods. *Significantly 
different from vehicle-treated control; n=9. 
5 1  
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Figure 5. continued. Figure 5 B shows apoptosis of human coronary artery endothelial 
cells induced by different P AHs. Cells were exposed to P AHs for 6 hrs and apoptosis 
was determined by detection of P ARP cleavage product (inactive form, ,..., 85 kD) as 
described in Materials and Methods. PARP cleavage caused by PAHs, 1 -MA, FL, 1 -MF, 
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Figure 6. Inhibition of P AH-induced apoptosis of human coronary artery endothelial cells 
by the Group VI and IV PLA2 inhibitor, MAFP. Cells were pretreated for 30 minutes 
with 10 µM MAFP or vehicle and exposed to 30 µM 1-MA, FL, 1-MF, 2-MF, FA, PA, or 
vehicle for 2 hr and apoptosis determined by detection of histone fragmentation as 



































Figure 7. PLA2 activity in HCAEC. Figure 7 A shows human coronary artery endothelial 
cells exhibit significant Group IVy activity. Assay conditions were optimized for 
characterization of Group IV enzymes and release of 14C-labeled arachidonic acid 
measured in the presence and absence of calcium, BEL or MAFP as described in 
Materials and Methods. PLA2 activity from EC lysate displayed significant activity that 
was not different in the presence and absence of calcium. MAFP, but not BEL, inhibited 
significantly cell-free PLA2 activity; n=9. *Significantly different from results obtained 
in the absence of protein (blank). #Significantly different from results obtained in the 
absence of inhibitor, p<0.05; n=9. 
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Figure 7. Continued. PLA2 activity in HCAEC. Figure 7 B shows treatment with PAHs 
does not enhance cell-free Group IVy activity. Cell lysates were treated with 1-MA, 1-
MF, PA, FA, or vehicle and cell-free PLA2 activity ev-aluated as described in the legend 
to Figure 6A. PLA2 activity was not significantly different in the presence and absence of 
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Figure 8. PLA2 activity in HCAEC. Figure 8 A shows human coronary artery endothelial 
cells exhibit significant Group VIP PLA2 activity. Assay conditions were optimized for 
characterization of Group Vlf3 PLA2 and release of 14C-linoleic acid measured as 
described in Materials and Methods. Endothelial cells displayed significant Group Vlf3 
PLA2 activity. Both MAFP and BEL inhibited significantly cell-free PLA2 activity. 
*Significantly different from results obtained in the absence of protein (blank). 
#Significantly different from results obtained in the absence of inhibitor, p<0.05; n=9. 
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Figure 8. Continued. PLA2 activity in HCAEC. Figure 8 B shows treatment with P AHs 
does not enhance cell-free Group VIP activity. Cell lysates were treated with 1-MA, 1-
MF, PA, FA, or vehicle and cell-free PLA2 activity evaluated as described in the legend 
to Figure 7 A. PLA2 activity was not significantly different in the presence and absence of 
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Figure 9. Effect of PAHs on expression of Group IVy and VI(3 PLA2 isoforms. PAH­
induced expression of PLA2 enzymes was determined by W estem blotting with 
antibodies specific for VI p and IVy PLA2 enzymes after treatment for 4 hrs with vehicle 
or active PAHs ( I -MA, FL, I -MF, FA, PA). I -MA, FA, and PA induced expression of 
both Group VI(3 and IVy enzymes; however, I -MF increased expression of only Group 
IVy, n=3. 
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· PART III: Polycyclic Aromatic Hydrocarbons Induce Apoptosis of 
Human Coronary Endothelial Cells: Evidence for the Involvement of 
Stress-Activated Protein Kinases, Caspases, and Phospholipases 
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INTRODUCTION 
Cigarette smoking (CS) is the number one cause of preventable, premature death in the 
United States today. It is a major risk factor for atherosclerosis and related 
cardiovascular diseases 1 • At present, approximately four million people worldwide die 
each year from tobacco-related cardiovascular diseases2• However, the exact 
pathophysiological mechanisms of smoking-induced heart disease have, not been fully 
established3 • 
Recent epidemiologic studies show a positive correlation between exposure to 
particulate air pollution or CS, and morbidity and mortality due to acute myocardial 
infarction2• CS was associated with a 50% increase in the progression of atherosclerosis 
and passive smoking was associated with a 25% increase4. Several clinical studies 
provide compelling evidence that the phospholipase A2 (PLA2)/arachidonic acid (AA) 
cascade plays an important role in the pathogenesis of smoking-induced cardiovascular 
diseases5•8 • In a 20 year retrospective study, smokers who ate a diet high in fish were 
significantly protected from morbidity and mortality due to acute myocardial infarction3• 
This protection was not seen in non-smokers. Moreover, several studies demonstrated 
that non-steroidal anti-inflammatory drugs protect significantly against the deleterious 
effects of smoking9 . Both of these interactions act by inhibiting the PLA2/ AA cascade, 
suggesting that this pathway is important in the mechanism by which smoking causes 
heart disease. 
Polycyclic aromatic hydrocarbons (P AHs) are an important class of 
environmental xenobiotics that are present in high concentrations in environmental 
pollution and in the tar fraction of CS7• Several studies using animal models have 
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demonstrated that P AHs present in high concentrations in CS and in environmental 
pollution promote atherosclerosis 1 •4 • Recent studies in our laboratory suggest that the 
mechanism of this effect may be at least, in part, due to PLA2/AA-mediated endothelial 
cells (EC) apoptosis. 
Injury to EC is an early and critical event in the development of atherosclerosis 
and smoking is known to augment EC injury. Smokers demonstrate a significant increase 
in EC death and loss into the circulation when compared to non-smokers5 • This injury to 
EC likely involves apoptosis or programmed cell death, since several studies indicate that 
apoptosis of EC is a key event during atherosclerosis5•8 • EC apoptosis is induced by 
several proatherosclerotic factors, thus suggesting the importance of EC apoptosis in 
atherogenesis. These factors include oxidized LDLs 1 , angiotensin 119, and high glucose 
concentrations 10• 
We found that P AHs may also promote atherosclerosis by inducing EC 
apoptosis 1 1 • We demonstrated that 1-methylanthracene, benzo( a )pyrene, and 
phenanthrene caused EC apoptosis by a mechanism that involved the PLA2/AA pathway. 
The three P AHs caused concentration and time-dependent release of 3H-arachidonic acid 
(3H-AA) from human coronary artery EC (HCAEC) and subsequent EC apoptosis. These 
effects were inhibited by 3 different PLA2 inhibitors, suggesting the involvement of 3 
different PLA2 isoforms in AA release and EC apoptosis 1 1 • Significant release of AA 
was seen within 10 minutes after exposure of EC to P AHs, however apoptosis was not 
seen until 2 hrs after treatment. Since apoptosis involves alteration in gene transcription, 
this delay in effect was likely due to an effect of the PLA2/ AA pathway on gene 
expression. 
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The PLA2/ AA cascade is complex with more than 100 biologically active 
mediators. Recent studies provide compelling evidence for a role of this cascade in 
apoptosis 12•1 3 • One mechanism by which AA induces apoptosis is by activation of stress­
activated protein kinases (SAPKs)/c-Jun-N-terminal kinases (JNKs) 14• 15 • Previous 
studies indicate that activation of PLA2 by oxidized LDLs contained within 
atherosclerotic plaques results in the release of AA and subsequent activation of 
SAPKIJNKs 16• These enzymes, of which 4 isoforms have been characterized (JNK-1, 
JNK-2, JNK-3, and p-38), phosphorylate and activate transcription factors such as c-jun 
and transcription factor activator protein-1 (AP-1 ), which play important roles in 
regulation of cell growth and apoptosis 17• The apoptotic pathway regulated by JNKs 
involves activation of caspases -8 and -9 that subsequently activate caspase-3 18 . 
Caspases are a family of cysteine-dependent, aspartate-specific proteases that 
work together in a cascade triggered by apoptosis signaling. Caspases are considered to 
be the major executioners in the apoptotic pathway. Caspase-3 cleaves the cytoskeletal 
and nuclear matrix proteins and causes intemucleosomal cleavage of DNA. One such 
protein is poly(ADP)ribose polymerase (P ARP), a nucleosomal protein that can be used 
as a marker of apoptosis when this enzyme is cleaved by caspase-3 fragments of 85 and 
31 kD19• Previous studies have shown that CS induces EC apoptosis through caspase-3 
activation in a dose-dependent manner18•20• However, the components of CS responsible 
were not elucidated. 
PAHs have been shown by others to activate JNKs and p-38; however upstream 
signal transduction mechanisms have not been determined 18 • Since oxidized LDLs have 
· been shown to be involved in EC apoptosis by a mechanism that involves AA and JNK, it 
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is possible that P AHs act in a similar fashion 1 • The purpose of this study was to test the 
hypothesis that P AHs induce EC apoptosis by a mechanism that involves PLAi-mediated 
activation of JNK.s, p-38, and caspases -8, -9, and -3. The following PAHs were studied, 
1-methylanthracene (1-MA), 2-methylanthracene (2-MA), anthracene (AN), fluorene 
(FL), 1-methylfluorene (1-MF), 2-methylfluorene (2-MF), phenanthrene (PA), and 
fluoranthene (FA). From previous studies, AN and 2-MA were shown to be inactive1 1 • 
These compounds were used as negative controls. 
MATERIALS AND METHODS 
Materials 
All P AHs were obtained from Aldrich (Milwaukee, WI). Methylarachidonoyl 
fluorophosphonate (MAFP), a Group IV and VI PLA2 inhibitor, was obtained from 
Biomol (Plymouth Meeting, PA). Anti-P ARP antibody, anti-caspases-3, -8, and -9, anti­
cleaved caspase-3 and CHAPS cell extract buffer and were obtained from Cell Signaling 
(Beverly, MA). Anti-phospho-p-38, anti-p-38, anti-c-Jun, and anti-phospho-c-Jun (anti­
p-c-Jun) antibodies were obtained from Santa Cruze (Santa Cruz, CA). The cell death elisa 
plus apoptosis kit was obtained from Roche (Indianapolis, IN). The caspase inhibitor Z-
V AD-FMK ( carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]- fluoromethylketone ), and 
SB203580 [ 4-( 4 '-Fluorophenyl)-2-( 4' -methylsulfinylphenyl)-5-( 4' -pyridyl) imidazole ] ,  a 
p-38 inhibitor, were purchased from Promega (Madison, WI). JNK inhibitor I (L form) 




HCAEC were obtained from Clonetics (San Diego, CA) and were maintained in 
microvascular EC growth medium (Clonetics, San Diego, CA) at 37° C in 5% CO2/95% 
02 • The cells were identified as EC based on morphology and staining for factor VIII 
antigen. Cells were grown to 80% confluency in petri dishes and treated with P AHs 1-
MA, 2-MA, AN, FL, 1-MF, 2-MF, PA, FA, or vehicle for various times (Figure 12). The 
cells were used between passage 4 and 7 for all the experiments. 
Determination of JNK-1 and -2 activation induced by PAHs 
Phosphorylation of JNK-1 and -2 was measured in cellular lysates from PAH-, or 
vehicle-treated cells in the presence and absence of the PLA2 inhibitor, MAFP (10 µM) 
and the JNK inhibitor, JNKI (L form) (1 µM). The activation and phosphorylation of 
JNK-1 and -2 were determined by Western blotting. After treatment for 90 min, plates 
were washed twice in cold phosphate buffer saline (PBS) and lysed with 1 50 µl ice-cold 
RIP A buffer containing 50 mM Tris, 150 mM NaCl, I% SDS, 0.5% sodium 
deoxycholate, I mM DTT, 100 µM p-4-(2-aminoethyl)-benzenesulfonyl fluoride, 1 µM 
pepstatin, I 00 µM leupeptin, and a phosphatase inhibitor (Sodium Orthovanadate ). The 
lysates were centrifuged at 10,000 g for 20 min and the supernatant subjected to 12% 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose 
membranes. The membranes were probed with antibodies against JNK-1 ,  -2, and 
phospho-JNK-1 and -2. Bands were visualized by enhanced chemiluminescence 
2 See all figures in appendix 
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(Amersham Pharmacia Biotech). Cells were pretreated with inhibitors 30 min prior to 
PAH treatment, cell lysates were collected and Western blotting performed. 
Determination of p-38 activation induced by P AHs 
Activation and phosphorylation ofp-38 was detected by Western blotting in PAH-, or 
vehicle (DMSO)-treated cells in the presence and absence of the PLA2 inhibitor, MAFP 
(10 µM) or the p-38 inhibitor, SB203580 (1 µM), to determine the involvement of this 
enzyme in P AH-induced apoptosis in HCAEC. Cells were treated with inhibitors for 30 
min and then treated with P AHs for 90 min. The cells were lysed and Western blotting 
performed. 
Phosphorylation of c-jun induced by P AHs 
Phosphorylation of c-jun was evaluated in lysates of EC after treatment with P AHs in the 
presence and absence of the PLA2 inhibitor (1 0 µM), MAFP, the inhibitor of JNK-1 and 
-2 (1 µM), JNK I (L form), and SB203580 (1 µM), the inhibitor of p-38. Cells were 
pretreated with inhibitors for 30 min and then treated with P AHs for 90 min. Then, the 
cells lysed and the Western blotting performed. 
Caspase activation induced by P AHs 
Activation of caspases including caspases -8, -9, and .:.3 has been shown to play an 
important role in apoptosis "induced by fatty acids such as AA 17• Caspases exist in the 
cell as proenzymes that are activated by cleavage. The effects of P AHs on caspase 
activation were determined using Western blotting with antibodies against cleaved 
caspases and procaspases. Caspase activation was assessed in cells exposed to P AHs for 
2 hrs. To determine the role of PLA2 isoforms in caspase-3 activation, Western blotting 
for caspase-3 was measured in PAR-treated cells in the presence and absence of the PLA2 
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inhibitor, MAFP, the caspase inhibitor (20 µM), Z-V AD-FMK, and the p-38 inhibitor, 
SB203580. Western analysis was performed as described above using a 1 X CHAPS cell 
extract buffer for cell lysis, and protein lysates subjected to 14 % polyacrylamide gel 
electrophoresis. CHAPS cell extract buffer contains 50 mM Pipes/KOH (pH 6.5), 2 mM 
EDTA, 0.1% CHAPS, 20 mg/ml Leupeptin, 10 mg/ml Pepstatin A, 10 mg/ml Aprotinin, 
and 5mM DTT. 
Apoptosis induced by P AHs 
Two methods were used to measure apoptosis caused by P AHs: Western blotting for the 
cleavage product of poly-ADP-ribose polymerase (P ARP) and ELISA for detection of 
histone fragmentation. 
P ARP cleavage was determined after treatment with P AHs or vehicle for 8 hr. 
Plates were washed twice with cold PBS and lysed in 150 µl ice-cold RIP A buffer 
containing 6 M urea. Cells were lysed by sonication on ice for 10 s, 40% duty and 
lysates centrifuged at 10,000 g for 20 min to remove cell debris. Protein lysates ( 40 µg) 
were subjected to 8% SDS-PAGE. Cells were pretreated for 30 min with the PLA2 
i_nhibitor, MAFP, the p-38 inhibitor, SB203580, the JNK inhibitor, JNK I (L form), or 
vehicle and then treated with P AHs for 8 hrs, and Western blotting done. 
Cellular DNA fragmentation ELISA 
Apoptosis was also evaluated fluorimetrically utilizing the Cell death elisa plus kit for 
detecting histone fragmentation. Cells seeded into 6-well plates were treated at 80-90% 
confluency with 30 µM P AHs or vehicle for 3 hrs. Histone fragmentation was evaluated 
in cells treated with all eight P AHs in the presence and absence of the PLA2 inhibitor 
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MAFP, the caspase inhibitor, Z-V AD-FMK, the p-38 inhibitor, SB203580, the JNK 
inhibitor, JNK I (L form), or vehicle. Cells were then washed with warm PBS, lysed and 
incubated with antihistone-biotin and anti-DNA-POD at room temperature for 2 hrs. 
After washing with incubation buffer, 100 µl of substrate solution was added to develop 
the color and measurements made at 405 nm. Additional preliminary experiments were 
performed to ensure that neither the P AHs nor the inhibitors interfered with this 
fluorescent assay. 
Statistical analysis 
Data are expressed as mean ± SEM. Data were analyzed by analysis of variance, and 
group means were compared using Student-Newman-Keuls'. Test appropriate 
transformations were performed on all data that did not follow a normal distribution ( e.g., 
percent data). In addition, when variances are not equal or if transformation failed to 
normalize the data, nonparametric statistics (Mann-Whitney rank sum test) were used. 
For all studies, the criterion for statistical significance was p<0.05. 
RESULTS 
JNK activation and phosphorylation 
Phosphorylation of JNK-1 and -2, was seen after 90 min of treatment with different 
active P AHs at 30 µM concentration. Only P AHs that activated the PLA2/ AA pathway 
caused JNK.-1 and JNK.-2 phosphorylation. Phosphorylation was detected after treatment 
with the active compounds, 1-MA, 1-MF, 2-MF, FA, FL, and PA, but not with the 
inactive compounds, 2-MA, AN, or control (Figure 2 A). PAR-induced JNK-1 and -2 
phosphorylation was inhibited significantly by MAFP (Figure 2 B). The JNK.-1 and -2 
67 
inhibitor (JNK I (L form), inhibited significantly the phosphorylation of JNK-1 and -2 
(Figure 2 C). 
PAR-induced phosphorylation of p-38 was seen after 90 min of treatment with 
different active P AHs at 30 µM concentration (Figure 3 A). No evidence of 
phosphorylation was detected after treatment with 2-MA, AN, or control. MAFP and 
SB203580 inhibited phosphorylation of p-38 (Figure 3 B, C). 
PAH-induced phosphorylation of c-jun 
c-jun is a transcription factor that is phosphorylated by p-38 and JNK-1 and -2 14 • To 
evaluate PAR-induced c-jun phosphorylation, Western blotting for phospho-c-Jun was 
performed in the presence and absence of MAFP, JNK I (L) form, and SB203580. Both 
MAFP and JNK I (L form) decreased phosphorylation of c-jun ( Figure 4 B, C); however, 
SB203580 was without effect (Figure 4 D). 
Caspase-3, -8, and -9 activation induced by P AHs 
We determined caspase-3, -8, and -9 activity by detection of the cleavage form of these 
enzymes, after 2 hrs of treatment with different P AHs. Only the P AHs that activated the 
PLA2/AA pathway caused caspase cleavage (Figure 5). Moreover, caspase-3 cleavage 
was inhibited significantly by MAFP and Z-V AD-FMK (Figure 6 B, C), but not by 
SB203580 (Figure 6 D). 
Induction of apoptosis by PAHs in HCAEC 
Apoptosis of EC induced by PAHs was evaluated by Western blotting for PARP 
cleavage. In addition, to measure the degree of apoptosis quantitatively, hi stone 
fragmentation was performed. Six out of nine compounds induced significant apoptosis 
as determined by Western blot analysis for the cleavage product of PARP (Figure 7 A). 
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1-MA, 1-MF, 2-MF, FL, FA, and PA, compo�ds that activated the PLA2/AA pathway, 
also induced apoptosis. The two compounds, AN and 2-MA, as well as the control, that 
did not cause 3H-AA release, did not induce apoptosis. Furthermore, PAR-induced 
apoptosis was inhibited by MAPP at a dose that inhibited PLA2 activity (see Part II) 
(Figure 7 B). The JNK inhibitor, JNK I (L form), also significantly attenuated P AH­
induced PARP cleavage (Figure 7 C); however, SB203580, the p-38 inhibitor, did not 
(Figure 7 D). 
1-MA, FA, 1-MF, 2-MF, FL, and PA induced histone fragmentation in HCAEC, 
however, there was no significant difference between AN and 2-MA when compared to 
control (Figure 8). Apoptosis in response to 1-MA, FL, 1-MF, 2-MF, FA, and PA was 
significantly inhibited by MAPP (Figure 9). Pretreatment with Z-V AD-FMK also 
inhibited PAR-induced histone fragmentation (Figure 10); however SB203580 did not 
alter this response (Figure 10). As can be seen in Figure 11, the JNK inhibitor, JNK I (L 
form), significantly inhibited P AH-induced apoptosis at a concentration that effectively 
inhibits c-jun phosphorylation. 
DISCUSSION 
P AHs, are important toxic constituents of CS and of environmental pollution. Numerous 
studies have implicated them in atherosclerotic vascular disease20; however, little is 
known about the specific cellular mechanisms of this effect. We demonstrated in 
previous studies that PAHs induce apoptosis of HCAEC an event important in the 
pathogenesis of atherosclerosis. Furthermore, we have demonstrated that the signal 
transduction pathway involves PLA2-mediated release of AA and other fatty acids. 
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In the present study we demonstrated that P AHs present in high concentrations in 
CS and in urban pollution induce phosphorylation of JNK- 1 ,  JNK-2, p-38, and the 
transcription factor c-jun. This effect was inhibited significantly by MAFP, an inhibitor 
of Group IV and VI PLA2 isoforms, suggesting a role for PLAi-mediated fatty acid 
release in phosphorylation of stress-activated kinases and c-jun. Inhibition of JNK-1 and 
JNK-2 activation with a peptide that acts by binding to the phosphorylation site and thus 
blocking phosphorylation (JNK-1 ;  L domain) significantly inhibited c-jun 
phosphorylation, cleavage of caspase-8, -9, and -3 and subsequent apoptosis. These 
results provide compelling evidence that P AHs induce apoptosis by a mechanism that 
involves fatty acid-induced phosphorylation of JNK-1 and JNK-2. Exposure to PAHs 
also induced phosphorylation of p-38 by a PLAi-mediated mechanism. Evidence for this 
is provided by the fact that PAR-induced phosphorylation was inhibited by MAFP. 
Interestingly, p-38 phosphorylation did not participate in the mechanism by which PAHs 
induce apoptosis since the p-38 inhibitor, SB203580, at a concentration that significantly 
attenuated p-38 phosphorylation, did not attenuate c-jun phosphorylation, caspase 
activation, or apoptosis. Although others have reported that P AHs induce JNK 
phosphorylation 1 8, to our knowledge this is the first report of a role for JNK 
phosphorylation in P AH-mediated apoptosis. 
This study also made the link between the discrete structure of these P AHs and 
their activity. 1 -MA, I -MF, 2-MF, FL, FA, and PA, that have bay- and/or bay-like 
regions (Figure 1 )  caused AA release, JNK. and c-jun phosphorylation, caspase cleavage, 
and apoptosis ofHCAEC. On the other hand, AN and 2-MA, which are linear structures 
did not have any of these effects. 
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Previous studies suggest that AA and other fatty acids can induce JNK and p-38 
phosphorylation in a time- and concentration-dependent manner21 • AA and linoleic acid 
activate JNK through activation of NADPH oxidase, an enzyme that is responsible for 
production of superoxide anion 17•22 • This finding was supported by the fact that 
superoxide anion generation parallel JNK. activation induced by various fatty acids. 
Moreover, AA-induced JNK activation can be blocked by antioxidant treatment2 1 • P AHs 
likely also induce JNK activation by a similar mechanism, since they have been shown to 
induce cellular oxidative stress23 • NADPH oxidase exists in its active form as a complex 
of several proteins and cofactors. AA induces a conformation is required to achieve 
proper assembly of the protein complex. P AHs may also act by facilitating the 
association of the protein complex with the membrane, since they have similar lipophility 
to AA. Future studies will focus on the role of oxidative stress on P AH-induced EC 
apoptosis. 
Apoptotic stimuli generate signals that are either transmitted across the plasma 
membrane to intracellular regulatory molecules or addressed directly to targets present 
within the cell. An example of the former mechanism is the Fas/Fas ligand/Fas 
associated death domain (FADD) pathway . . Binding of Fas ligand to Fas recruits the 
death domain protein, F ADD, which is required for caspase-8 activation and subsequent 
initiation of lethal proteolytic cascades. F ADD couples the Fas death receptor to 
procaspase-8, subsequent oligomerization promotes procaspase-8 autoactivation 19•24-28• 
· In the current study, we provide strong evidence that P AHs act in this way (i.e., by 
inducing JNK. phosphorylation and subsequent caspase activation). The latter mechanism 
involves the regulation of mitochondrial function by the BCL-2 family of proteins. 
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Release of cytochrome c from the mitochondria is a proapoptotic signal. Proapoptotic 
protease activating factor (Apaf-1) is activated upon biding with cytochrome c after its 
release from the mitochondria. The antiapoptotic Bcl-2 proteins downregulate apoptosis 
by either preventing cytochrome c release directly, or by sequestering Apaf-125. There is 
also a reciprocal regulation f Bcl-2 by cytochrome c. Apoptotic signals can block Bcl-2 
function, which in turn causes mitochondrial membrane depolarization and subsequent 
cytochrome c release, proteolytic activation of procaspase-9 and subsequent activation of 
caspase-3 and other lethal proteolytic cascades25. 
In the present study, we provide convincing evidence that PAHs act by activating 
the intracellular regulatory protein FADD. We did not, however, rule out additional 
mechanisms of P AH-induced apoptosis. P AHs may cause release of cytochrome c by a 
direct effect or indirectly by inhibiting Bcl-2. All active compounds tested, but not the 
inactive compounds, caused poly(ADP-ribose) polymerase (P ARP) cleavage to its 
inactive form. This cleavage was inhibited with PLA2 and JNK-1 and -2 inhibitors but 
not with a p-38 inhibitor. These data provide evidence for the involvement of the 
PLA2/AA pathway as well as JNK-1 and -2, but not p-38, in PAH-induced PARP 
cleavage. These results were confirmed using another measure of apoptosis,. histone 
fragmentation. The cleavage of PARP is mediated by caspase-3. Cleavage of PARP by 
caspase-3, causes production of cleavage products that cannot repair DNA damage, thus, 
PARP cannot prevent caspase-induced cleavage of intemucleosomal DNA 18. Caspase-3 
is an effector caspase that has a short prodomain and mediates apoptosis by destruction of 
cellular contents and activation of the machinery that degrades DNA 1 5· 1 8. Caspase-3 is 
responsible for dissolution of the nucleus ( chromatin condensation and DNA 
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fragmentation) and cleavage of the cytoskeletal and nuclear matrix proteins. Caspase-3 
also causes intemucleosomal cleavage of DNA. P ARP plays a crucial role in DNA repair 
as well as replication, transcription, and cell death. 
Many studies have investigated the role of CS in vascular cell injury. In one 
study 20 Chinese passive smokers that had been exposed to tobacco smoke > 8 hrs a day 
for 2 to 24 years, were shown to have impaired endothelial production and bioavaliability 
of nitric oxide (NO), enhanced platelet aggregation, coronary artery spasm, and a 
pathological lipid profile20 . Wang and his colleagues showed that CS induces EC 
apoptosis, in a dose dependant-manner by a caspase-3 mediated mechanism. They 
concluded that EC apoptosis likely contributes to and initiates atherosclerosis 1 8 . In 
another study, they demonstrated that acute CS exposure was associated with increase in 
oxidative stress, mitochondrial dysfunction, and cytochrome c release in macrophages. 
This effect is likely important in the light of the fact that macrophages play an important 
role in EC injury during atherosclerosis 1 8• Our results confirm and extend the results of 
Wang and colleagues. They showed that CS induces apoptosis by a caspase-3-mediated 
mechanism, but they did not identify components of CS responsible for this effect. Our 
study provides strong evidence that the P AHs we studied may be responsible, at least in 
part, for this effect. 
Six of the P AHs were active in inducing apoptosis but two were not. The 
structural feature that the six compounds shared was the presence of one or more bay or 
bay-like regions in the molecule. The inactive compounds had linear structures. This 
discrete structure-activity relationship suggests that P AHs may act by binding to 
receptors or other proteins in the cell. The signal transduction pathway targeted by P AHs 
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is the same as that targeted by the Fas/Fas Ligand death pathway, suggesting that P AHs 
may bind the Fas receptor. The role of the Fas receptor in P AH-induced apoptosis is the 
subject of future investigation. The presence of a discrete structure-activity relationship 
may be useful for predicting toxicity of the P AHs present in CS. Future studies will 
focus on further defining this relationship. 
Many studies have investigated the role of large molecular weight P AHs such as 
benzo( a )pyrene and dimethyl benzanthracene in atherosclerosis29• However, this is the 
first report of a potential role for small molecular weight P AHs. The small molecular 
weight P AHs are significantly more water-soluble than large molecular weight 
compounds, as a result, they are more bioavaliable. One study showed that 95% of 14C­
phenanthrene was absorbed into the arterial system of pigs after oral administration while 
only 33% ofbenzo(a)pyrene reached the circulation30• The presence of these compounds 
. in high concentration in CS and urban pollution in addition to the effectiveness of their 
absorption into the circulation lends credence to the possibility that they are important in 
the progression of atherosclerotic vascular disease. 
SUMMARY 
P AHs are important toxic constituents of CS and of environmental pollution. Numerous 
studies have implicated them in atherosclerotic vascular disease20 • Our results 
demonstrate that P AHs present in high concentrations in CS and in urban pollution 
induce phosphorylation of JNK-1, JNK-2, p-38, and the transcription factor c-jun. This 
effect is inhibited significantly by MAFP, .an inhibitor of Group IV and VI PLA2 
isoforms, suggesting a role for PLAi-mediated fatty acid release in phosphorylation of 
74 
stress-activated kinases and c-jun. We also found that pretreatment with JNK-1 and -2 
inhibitor (JNK-1 L form) significantly inhibits c-jun phosphorylation, cleavage of 
caspase-3 and subsequent apoptosis (P ARP cleavage and histone fragmentation). These 
results provide compelling evidence that P AHs induce apoptosis by a mechanism that 
involves fatty acid-induced phosphorylation of JNK-1 and JNK-2. Furthermore, p-38 
phosphorylation did not participate in the mechanism by which P AHs induce apoptosis as 
the p-38 inhibitor, SB203580, at a concentration that significantly attenuate p-38 
phosphorylation, did not attenuate c- jun phosphorylation, caspase activation, or 
apoptosis. This study also establishes a link between the discrete structure of these P AHs 
and their activity. The presence of bay- and/or bay-like regions in some compounds 
causes AA release, JNK and c-jun phosphorylation, caspase cleavage, and apoptosis of 
EC. Oq. the other hand linear structures did not have any of these effects. This discrete 
structure-activity relationship suggests that P AHs may act by binding to receptors or 
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APPENDIX 
8 1  
1 -m ethylanthracene 
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1 2 0- 1 2-7 
F luore n e  
8 6 -7 3 -7 
2-m ethylfluorene 
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2 0 6 -4 4 -0 
CH 3 
Figure 1: Structures of polycyclic aromatic hydrocarbons. Antrhracene (AN) and 2-
methylanthracene (2-MA) are linear structures. 1-metheylanthracene (1-MA) and 1-
methylfluorene ( 1-MF) have bay-like region formed by methyl group. Fluqrene (FL), 2-
methylfluorene (2-MF), fluoranthene (FA), and phenantherene (PA) have bay-region. 
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Figure 2. PAR-induced phosphorylation of JNK-1 and JNK-2. Cells were exposed to 
PAHs for 90 min with or without the PLA2 inhibitor, MAFP, ( 10  µM), or the JNK 
inhibitor, JNK I (L form) (1 µM). Cells were pretreated with inhibitors for 30 min prior 
to treatment with PAHs (30 µM), cell lysed, and JNK-1 and -2 phosphorylation 
determined by immunoblotting with an antibody against phospho-JNK-1 and -2. Panel A 
shows phosphorylation of JNK-1 and -2 after treatment with FL, FA, 2-MF, 1 -MA, PA, 
and 1 -MF but not AN, 2-MA, or vehicle. JNK phosphorylation was inhibited by MAFP 
(panel B) and by the JNK inhibitor, JNK I (L form) (panel C). n=3. 
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Figure 3. PAH-induced phosphorylation ofp-38. Cells were exposed to PAHs for 90 min 
with or without the PLA2 inhibitor, MAFP (10 µM) or the p-38 inhibitor, SB203580 (1 
µM). Cells were pretreated with inhibitors for 30 min prior to treatment with P AHs (30 
µM), cells lysed and p-38 phosphorylation determined by immunoblotting with an 
antibody against phospho-p-38  (pp-38). Panel A shows phosphorylation ofp-38 after 
treatment with FL, FA, 2-MF, 1-MA, PA, and 1-MF but not AN, 2-MA, or vehicle. p-38 
phosphorylation was inhibited by MAFP (panel B) and to lesser extent by SB203580 
(panel C). n=3. 
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Figure 4. PAH-induced phosphorylation of c-jun. Cells were exposed to P AHs for 90 
min with or without the PLA2 inhibitor, MAFP (10 µM), the p�38 inhibitor, SB203580 (1 
µM), or the inhibitor of JNK-1 and-2, JNK I (L form), (1 µM). Cells were pretreated 
with inhibitors for 30 min prior to treatment with P AHs (30 µM), lysed, and c-Jun 
phosphorylation determined by immunoblotting with an antibody against phospho-c-jun 
(p-c-jun). Panel A shows a increase in phosphorylation of c-jun after treatment with FL, 
FA, 2-MF, 1 -MA, PA, and 1 -MF, when compared to control. No such increase was 
observed with AN or 2-MA. c-Jun phosphorylation was inhibited by MAFP (panel B), 






















Figure 5. Cleavage of caspases-3, -8, and -9 induced by P AHs. HCAEC were treated 
with different P AHs (30 µM) for 2 hrs, and total proteins were isolated. Equal amounts of 
proteins (40.0 µg) were subjected to immunoblot analysis as described in Materials and 
Methods. Panel A, B, and C show the cleavage of caspases (50 kD proactive enzyme, 36 
kD intermediate inactive form or 16 kD active form) and activation of caspases-3, 8, and 
9, respectively. n=3. 
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Figure 6. Effects ofMAFP (10 µM), Z-VAD-FMK (20 µM), and SB203580 (1 µM), on 
P AH-induced caspase cleavage. Pretreatment with MAFP and Z-V AD-FMK abolished 
caspase-3 cleavage (panel B, C); however, SB203580 was without effect (panel D). n=3. 
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Figure 7. Apoptosis of human coronary artery endothelial cells induced by different 
P AHs, P ARP cleavage. Cells were exposed to P AHs for 8 hrs with or without the PLA2 
inhibitor, MAFP (10 µM) the p-38 inhibitor, SB203580 (1 µM), or the inhibitor of JNK-1 
and -2, JNK I (L form). Apoptosis was determined by detection of PARP cleavage 
product (inactive form, ,.., 85 kD) as described in Materials and Methods. Panel A shows 
PARP cleavage caused by PAHs, 1-MA, FL, 1-MF, 2-MF, FA, and PA but not with 2-
MA, AN, or vehicle. PARP cleavage was inhibited by MAFP (panel B), and JNK I (L) 
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Figure 8. Apoptosis of human coronary artery endothelial cells induced by different 
P AHs, histone fragmentation. Cells were exposed to P AHs for 3 hrs. Apoptosis 
determined by detection of histone fragmentation as described in Materials and Methods. 
1 -MA, FL, 1 -MF, 2-MF, FA, and PA caused significant histone fragmentation. 
However, 2-MA, AN, or vehicle did not cause histone fragmentation. *Significantly 
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Figure 9. Inhibition of apoptosis of human coronary artery endothelial cells induced by 
MAFP (10 µM). Cells were pretreated for 30 min with MAFP prior to treatment with 30 
µM 1 -MA, FL, 1 -MF, 2-MF, FA, PA, or vehicle for 3 hrs and apoptosis determined by 
detection of histone fragmentation as described in Materials and Methods. MAFP caused 
significant inhibition of histone fragmentation. *Significantly different from vehicle­
treated control; n=3. 
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Figure 10. Inhibition of apoptosis of human coronary artery endothelial cells induced by 
the caspase inhibitor, Z-V AD-FMK (20 µM) but not the p-38 inhibitor, SB203580 (1 
µM). Cells were pretreated for 30 min with inhibit�r prior to treatment with 30 µM I ­
MA, FL, 1-MF, 2-MF, FA, PA, or vehicle for 3 hrs and apoptosis determined by 
detection of histone fragmentation as described in Materials and Methods. Z-VAD-FMK · 
caused significant inhibition ofhistone fragmentation; however, SB203580 did not. 
*Significantly different from vehicle-treated control; # Significantly different from P AH­
treated EC in the absence of inhibitor; n=3. 
91  
- PAH 
� P AH+ JNK I (L form) 
1.2 
-¥ �¥ # # 
1.0 -












... * * * 
0.2 
0.0 






> r �1 "'� �I' 
I I I I I I I 
DMSO 1-MA 1-MF 2-MF FL FA PA 
Polycyclic Aromatic Hydrocarbons 
Figure 1 1 . Inhibition of apoptosis of human coronary artery endothelial cells induced by 
the JNK I inhibitor, JNK I (L form) ( 1  µM). Cells were pretreated for 30 min with 
inhibitor prior treated with 30 µM 1-MA, FL, I -MF, 2-MF, FA, PA, or vehicle for 3 hrs 
and apoptosis determined by detection of histone fragmentation as described in Materials 
and Methods. Inhibition of JNK-1 and -2 induced significant inhibition of histone 
fragmentation. *Significantly different from vehicle-treated control; # Significantly 
different from EC treated with PAHs in the absence of inhibitor p<0.05 ; n=3. 
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PART IV: · Identification and Characterization of Phospholipase A2 
isoforms targeted by Polycyclic Aromatic Hydrocarbons in Vascular 
Smooth Muscle Cells 
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INTRODUCTION 
Atherosclerotic vascular diseases are the major sequelae of smoking in adults and of 
passive exposure to tobacco smoke in non-smokers1 . Cigarette smoking (CS) causes 
endothelial cells (EC) dysfunction, mononuclear cells infiltration, cholesterol deposition, 
platelet aggregation, smooth muscle proliferation, and plaque rupture2• Acute coronary 
thrombosis resulting from rupture of an atherosclerotic plaque accounts for 
approximately 50% of deaths due to myocardial infarction. Vascular smooth muscle 
cells (SMC) are responsible for production of interstitial collagen that is important for 
maintenance of tensile strength of the fibrous plaque3'4 • Recent studies indicate that SMC 
apoptosis is a major contributing factor to plaque rupture, and subsequent myocardial 
infarction1•3 • When these cells die, the loss of collagen formation results in decrease 
tensile strength of the plaque, which ultimately leads to plaque rupture3 • CS significantly 
increases the incidence of plaque rupture and subsequent acute coronary thrombosis. 
Moreover, vascular biopsies from smokers demonstrate significantly more SMC 
apoptotic cell death when compared to biopsies from nonsmokers. Similar results have 
been shown in vitro, after exposure of human vascular cells to CS extract, but the 
causative components in CS responsible for this effect have not been identified 1•5 . 
Several key processes that occur during atherosclerosis involve arachidonic acid 
(AA) and its metabolites6 • The AA pathway has been implicated in EC 
dysfunction/death, platelet and inflammatory cell activation, and alteration of SMC 
growth and differentiation. The mechanism by which this pathway promotes 
atherogenesis involves second messenger functions of AA and its metabolites. AA is 
released from membrane phospholipids by the action of a variety of intracellular 
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phospholipases; including phospholipases C, D, and A2• The majority of free AA is 
derived from the activity of phospholipases A2 (PLA2), which cleave AA directly from 
the sn-2 position of membrane phospholipids 7•8 • 
Over ten different families of PLA2 have been characterized to date. These 
enzymes are classified according to whether their active site contains a serine or a 
histidine residue9• In general, low molecular weight secreted isoforms (Groups I, II, III, 
V, IX, and X) have a histidine at the active site; whereas the high molecular weight 
intracellular enzymes (Groups IV and VI) as well as low molecular weight (Group VII 
and VIII PLA2s) have an active site serine. Of the Groups IV and VI, several isoforms 
have been identified9-1 1 • 
Three enzymes have been characterized from Group IV. These include a 
calcium-dependent PLA2 (Group IV cPLA2) that is arachidonoyl-selective and plays an 
essential role in eicosanoid biosynthesis 10• It is regulated by phosphorylation and 
requires calcium in order to bind to the nuclear membrane during activation9• 1 0 . More 
recently, two new members of this family have been identified. These are designated as 
Group IVf3 and 1Vy12 . Group IVf3 is a 114 kD cytosolic protein that is calcium-dependent 
with a broad substrate specificity i.e., it will cleave several different fatty acids from the 
sn-2 position. Group IVy is a 61 kD membrane bound protein that has a stricter substrate 
specificity i.e. it will cleave other fatty acids from the membrane but it prefers to interact 
with palmitic or AA. This enzyme has sequential lysophospholipase activity as well9- 13• 
After cleaving the sn-2 fatty acid it will cleave the fatty acid from the sn- 1 position. 
Several inhibitors have been developed that target these three enzymes. In general, these 
inhibitors are analogues of AA and act by competing with substrate for enzyme binding. 
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These include methylarachidonoyl fluorophosphonate (MAFP) and trimethylfluoro 
ketone (AACOCF3)11 • Since these inhibitors act by binding the active site serine, they 
are also effective inhibitors of Group VI enzymes 11. 
Three isoforms have been characterized from the Group VI family. The first to be 
identified was the Group VIa enzyme found in cardiac muscle. This enzyme is a 40 kD 
calcium-independent, arachidonoyl-selective enzyme that prefers plasmenylcholine 
phospholipids9·11. Group VIJ3, of which two splice variants have been identified, is an 
85-88 kD membrane bound protein that is arachidonoyl nonselective and calcium­
independent9-12. These enzymes are specifically inhibited by bromoenol lactone (BEL), a 
suicide substrate that irreversibly binds the active site of the enzyme11 • 
Several laboratories have reported the involvement of group IV a cPLA2 and VIJ3 
iPLA2 in apoptotic signal transduction pathways 7,13-13. Past reports indicate that Group 
IVa is involved in tumor necrosis factor-a (TNF-a) -induced apoptosis. Cells from 
Group !Va-knock-out mice are resistant to the effects of TNF-a18; however, Fas/FasL 
has been shown to be equally effective in mediating apoptosis in Group IVa positive and 
negative cell lines13 • These data suggest that this enzyme is not a critical mediator of 
Fas/FasL-induced apoptosis. 
Several studies have implicated Group Vlf3 in apoptotic cell death caused by the 
Fas/Fas-associated death domain (FADD) pathway6•17• Upon activation of Fas, Group 
VIJ3 causes release of fatty acids that induce phosphorylation of stress-activated kinases 
(i.e., c-jun-N-terminal kinases and p-38). These kinases cause downstream activation of 
transcription factors and caspases. Moreover, there is a positive feedback loop identified, 
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wherein fatty acid-induced caspase activation causes reciprocal VI� cleavage. The 
cleaved product exhibits a 2- to 3-fold increase in PLA2 activity, thus further driving the 
process of apoptosis6 • 
We have demonstrated recently that polycyclic aromatic hydrocarbons (P AHs) 
present in the tar fraction of CS and in environmental pollution induce apoptosis of human 
coronary artery EC (HCAEC) by a mechanism that involves activation and increased 
expression of at least 2 isoforms of PLA2 1 7. Substituted and unsubstituted fluorene 
compounds activate only the Group IVy enzyme. Fluorene-induced activation of this enzyme 
is essential for the mechanism by which these P AHs induce EC apoptosis. In contrast, P AHs 
such as 1-methylanthracene, fluoranthene, or phenanthrene induced apoptosis by activating 
both Group IVy and Group VI�. Furthermore, discrete structural determinants were required 
for activation of PLA2 and apoptosis. Linear compounds were inactive, whereas compounds 
containing bay- or bay-like regions increased the expression and activation of the two PLA2 
isoforms listed above 1 7• We have also demonstrated that PAR-induced apoptosis of EC 
involves a pathway similar to the Fas/F ADD pathway in that it involves PLAi-mediated 
phosphorylation of JNK-1 and-2 and subsequent activation of caspases -8, -9, and -3. 
Since SMC apoptosis is also a significant event in the pathogenesis of atherosclerosis, 
experiments were performed to investigate the effects of P AHs on SMC in vitro and to 
characterize the roles of different PLA2 isoforms in this effect. In addition, we evaluated the 
effects of P AHs on F ADD expression to investigate whether P AHs interact with this 
pathway. The following PAHs were examined: 1-methylanthracene (1-MA), triphenylene 
(TRI), phenanthrene (PA), fluoranthene (FA), 1-methylfluorene (1-MF), 2,3 benzofluorene 
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(2,3 BF) anthracene (AN), and chrysene (CH) (Figure 13). These compounds were chosen 
because they are found in high concentrations in the environment and in tobacco smoke and 
are among the 16 EPA priority P AHs because of their toxic potential. 
MATERIALS AND METHODS 
Materials 
All P AHs were obtained from Aldrich (Milwaukee, WI) [ 5-6,8-9, 1 1- 12, 14-15-3H] . 
Arachidonic acid {3H-AA; 200-240 Ci/mmol) and phosphatidylcholine, L-a.-1-palmitoyl-
2-arachidonoyl-[ arachidonoyl-1-14C] (14C-AA) were purchased from American 
Radiolabeled Chemicals (St. Louis, MO). L-a.-phosphatidylcholine, P-arachidonoyl-v­
palmitoyl (C:20:4, [cis]-5,8,11, 14/C: 16) (PC-AA) and L-a.-phosphatidylcholine, p­
linoleoyl-v-palmitoyl (C 18 :2, [cis]-9,12/C 16:0) (PC-LA) were obtained from Sigma­
Aldrich (St. Louis, MO). L-3-phosphatidylcholine, 1-palmitoyl-2-[2-14C]linoleoyl ( 14C­
LA) was purchased from Amersham Pharmacia Biotech (Piscataway, NJ). Bromoenol 
lactone (BEL), a Group VI PLA2 inhibitor, and methylarachidonoyl fluorophosphonate 
(MAFP), a Group IV and VI PLA2 inhibitor, were obtained from Biomol (Plymouth 
Meeting, PA). Cell death elisa plus apoptosis kit was obtained from Roche (Indianapolis, 
IN). Antibodies for poly-ADP-ribose polymerase (P ARP), caspase-3, and CHAPS cell 
extract buffer were obtained from Cell Signaling (Beverly, MA). Anti-F ADD and anti-p­
F ADD were obtained from Santa Cruze (Santa Cruz, CA). 




Human aortic smooth muscle cells (SMC) were obtained from Clonetics (San Diego, 
CA). Cells were cultured in smooth muscle cell growth medium-2 supplemented with 
5% fetal bovine serum (FBS), 2 ng/mL human basic fibroblast growth factor, 0.5 ng/mL 
human epidermal growth factor, 50 µg/mL gentamicin, 50 µg/mL amphotericin-B, and 5 
µg/mL bovine insulin. For all experiments, early passage cells were grown to 80-90% 
confluence and made quiescent by serum starvation (0.1 % FBS) for at least 24 hrs. 
Determination of P AH-induced fatty acid release from prelabeled cells 
To determine the effect of various P AHs on fatty acid release, cells were seeded into 6-
well culture plates at a density of 3Xl 05 cells/well and grown to 75% confluency. Cells 
were prelabeled with 0.25 µCi/ml of 3H-arachidonic acid {3H-AA) (specific activity=180-
240 Ci/mM;) for 24 hrs 17• To determine total cellular uptake of 3H-AA, the cells at 80-
90% confluency were washed twice with Hanks' balanced salt solution (HBSS) and 
equilibrated for 45 min in HBSS + 0.1 % bovine serum albumin (BSA) to inhibit 
reacylation and metabolism of released 3H-AA. Radio labeled cells were exposed to 
various concentrations (1-40 µM) of 1-MA, 1-MF, PA, FA, AN, TRI, 2,3 BF, CH, or 
vehicle, for 1 hr. Cumulative release of 3H-AA into the medium was measured by 
scintillation counting and expressed as percent of total cellular radioactivity. 
Characterization of PLA2 isoforms 
Release of 3H-AA into the medium was determined in cells treated with P AHs, with and 
without the Group IV and VI specific PLA2 inhibitors, MAFP and BEL. Cells were 
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preincubated for 30 min with MAFP (1 0 µM) or BEL (7 .5 µM) before the treatment with 
PAHs (30 µM) or vehicle (DMSO). 3H-AA release was determined as described above. 
Characterization of PLA2 isoforms present in SMC was determined by cell-free PLA2 
assays, reverse-transcriptase polymerase chain reaction {RT-PCR), and Western blotting. 
Cell-free PLA2 activity was measured in whole cell sonicates as described previously 1 8• 
Cells were washed in Ca2+-free PBS containing 5 mM EDTA and 1 mM PMSF, 
resuspended in cold homogenizing buffer, placed on ice, and sonicated. Light 
microscopy was used to verify that the cells were broken. Based on previous inhibitor 
studies, experiments were designed to assay for Groups IV a, f3, y and Vlf3 enzymes. 
Since Groups IVa and IVy prefer AA over linoleic acid at the sn-2 position, the 
substrates 1 -palmitoyl-2- [arachidonoyl-1 - 14C] phosphatidylchline { 14C-AA-PC; 1 µM)/ 
unlabelled AA-PC (1 0 µM) was used to assay for their activities. Since Groups 1Vf3 and 
Vlf3 are arachidonoyl-nonselective, the substrate 1 -palmitoyl-2-linoleoyl [linoleoyl-1 -
14
C] phosphatidylcholine {14C-LA-PC; 1 µM)/unlabeled LA-PC (1 0 µM) was used to 
assay for their activities. Substrates were dried under nitrogen and resuspended by 
sonication in assay buffer to a final optimum concentration as determined in preliminary 
experiments . To determine the role of calcium in activation of PLA2, assays were 
performed in the presence of either 5 mM CaCli or 5 mM EGTA. To determine if PAHs 
activate PLA2 enzymes by interacting directly with the proteins, cell lysates were 
incubated with 1 4C-AA-PC/AA-PC or 14C-LA-PC/LA-PC for 30 min in the presence and 
absence of PAHs. To determine whether PAHs activate PLA2 directly, experiments were 
also- performed in the presence and absence of inhibitors (MAPP and BEL) to validate the 
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selectivity of inhibitors for specific isoforms. Cell-free PLA2 assays are designed to 
target select isoforms and therefore, are effective means to validate the specificity of 
inhibitors for select PLA2 isoforms. Reactions were terminated by addition of 
chloroform-meth�ol, 2:1 (v/v), the chloroform layer extracted and spotted on silica gel 
thin layer chromatography plates. The plates were chromatographed in a neutral lipid 
solvent and the lipids visualized with Ii vapor. The zones corresponding to fatty acid and 
phospholipid were cut out and radioactivity determined by scintillation counting. 
Reverse transcription-polymerase chain reaction {RT-PCR) for PLA2 isoforms expressed 
by SMC 
To determine the expression of different PLA2 isoforms, RT-PCR was performed as 
described previously. Total cellular RNA was isolated from SMC (10-20 x 106 cells) 
using NucleoSpin nucleic acid purification kits (Clontech, Palo Alto, CA) according to 
instructions of the manufacturer. RNA was isolated from SMC using guanidine 
isothiocyanate-CeCl ultracentrifugation. Concentration of the RNA was determined by 
absorbance at 260 nm. For the RT reaction, 2.5 µg of RQl -treated RNA, 1 µg of 
oligo( dT) 12. 18 primers (Life Technologies, Inc., Grand Island, NY), and 10 mM dNTPs in 
nuclease-free water were heated to 65 °C for 5 minutes and then placed on ice for 1 min. 
To this solution 0.1 M DTT, 40 units of RNase OUT (recombinant RNase inhibitor), and 
10 X buffer (100 mM Tris-HCI [pH 8.31), 500 mM KCl, and 25 mM MgCh) were added 
in a final volume of 20 µ1. The reaction mixture was incubated at 42 ° C for 2 min, 200 
units of M-ML V reverse transcriptase was added and incubated for 42 °C for 90 min, and 
the reaction was terminated at 70 °C for 15 min then placed on ice. A negative control 
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reaction was performed without the M-ML V. Four sets of downstream and upstream 
primers for PLA2 Group IVa., p, y, and Group Vlfl have been synthesized previously and 
were used in the PCR reaction. Primers used for PCR were: PLA2 group IV a. (sense, 5 ' ­
CCAAATGTCATITATAGATCC-3 '); PLA2 group IVa. (antisense, 5 ' ­
CATGAACTATGCTTTGGGTITAC-3'); PLA2 group IV(} (sense, 5 ' ­
ACTGAGTGCCCTGCCCTCTGGTCAAG-3'); PLA2 group IV(} (antisense, 5'­
TGCCCATAAAGAACTCGGAGCCAAAGA-3 '); PLA2 group IVy (sense, 5 '­
AGAAAGAAGAAAAGGCGGCCGTGGAGAGAC-3 '); PLA2 group IVy (antisense, 5 ' ­
CGGCACTGAAGTCGAAGGAGAGGATGAGGT-3 '); PLA2 group Vlfl (sense, 5 ' ­
ATGCAGTTCTITGGCCGCCTGGTCAAT-3 '); PLA2 group VI(} (antisense, 5 ' ­
TGATGATCATCTCCGCACACCCCTTCTG-3 '). PCR reactions were performed using 
T AQ polymerase, products recovered and a portion analyzed by 1 .5 % agarose gel 
electrophoresis to determine the size. 
W estem blot analysis for PLA2 isoforms 
After treatment with 30 µM of 1-MA, 1 -MF, FA, TRI, PA, CH, AN, 2,3BF, or vehicle, 
cells were washed with cold PBS and then lysed in RIPA buffer (50 mM Tris, 1 50 mM -
NaCl, 1 % SDS, 0.5% sodium deoxycholate, 1 mM DTT, 100 µM p-4-(2-aminoethyl)­
benzenesulfonyl fluoride, 1 µM pepstatin, 1 00 µM leupeptin, and sodium orthovanadate ). 
The lysates were centrifuged at 10,000 g for 20 min and the protein concentrations 
determined. Equal concentrations of protein were subjected to 8% or 10% SDS- _ 
polyacrylamide gel electrophoresis (SOS-PAGE) and transferred onto nitrocellulose 
membranes. The membranes were probed with antibodies against Group IV a. PLA2 , VIP 
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PLA2, and IVy PLA2 (a gift from Dr. Christina Leslie). Bands were visualized by 
enhanced chemiluminescence (Amersham Pharamacia Biotech). 
Overexpression of PLA2 isoforms in SMC 
Characterization of PLA2 isoforms, targeted by specific P AHs, was further verified by 
transiently overexpressing PLA2 isoforms in SMC. A full-length cDNA encoding the 
human PLA2 Group IVy (accession number XM_0091 19), and PLA2 group VIJ3 
(accession number XM_039248) was generated using a template obtained from SMC via 
RT-PCR. The cDNAs were ligated into a PCR 3.1 vector (Invitrogen) of the TA cloning 
system for subcloning and sequencing. PCR3. l expression vectors containing PLA2 
cDNAs were transfected into cells using the Superfect transfection method (Qiagen). 
Positive clones were selected, and clones with the highest expression levels were 
identified by Western blotting and used for transfection. Wild type SMC and SMC 
overexpressing either group IVy or group Via were pre-labeled with 3H-AA for 24 hrs 
and exposed to I -MA, FA, TRI, PA, or vehicle for 1 hr. Release of 3H-AA into the 
medium was measured and results expressed as fold change in activity (3H-AA release 
from overexpressing cells/ 3H-AA release from wild type). 
Measurement/analysis of apoptosis induced by P AHs 
W estem blot analysis for the cleavage product of P ARP and caspase-3 was used to 
measure apoptosis. In addition, F ADD phosphorylation was determined. 
The activation and phosphorylation ofFADD was analyzed by Western blotting. 
After treatment for 2 hrs with P AHs or vehicle, plates were washed twice in cold PBS 
and lysed with 1 50 µl ice-cold RIP A buffer. The lysates were centrifuged at 1 0,000 g for 
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20 min and the supematants were subjected to 12% SDS-PAGE and transferred onto 
nitrocellulose membranes. The membranes were probed with antibodies against F ADD 
and phospho-F ADD. Bands were visualized by enhanced chemiluminescence. 
The effects of PAHs on caspase-3 activation were determined using Western 
blotting using antibodies against cleaved (active) caspases and procaspases. Caspase-3 
activation was assessed in cells exposed to P AHs for 3 hrs. Cells were lysed in CHAPS 
(50 mM Pipes/KOH (pH 6.5), 2 mM EDTA, 0.1% Chaps, 20 mg/ml Leupeptin, 10 mg/ml 
Pepstatin A, 10 mg/ml Aprotinin, 5 mM DTT), and protein lysates subjected to 14 % 
- SDS-PAGE. 
For detection of P ARP cleavage, cells were treated with different P AHs for 6, 8, 
and 12 hrs. ·cells were washed twice with cold PBS and lysed in 100 µl ice-cold RIPA 
buffer containing 6 M urea. Cells were lysed by sonication on ice for 2 times at 30% 
duty and lysates were centrifuged at 10,000 g for 20 min to remove cell debris. Protein 
lysates were subjected to 8% SDS-PAGE. 
Statistical analysis 
Data are expressed as mean ± SEM. The data were analyzed by analysis of variance 
(ANOV A), and group means were compared using Student-Newman-Keuls' .  Test 
appropriate transformations were performed on all data that did not follow a normal 
distribution (e.g., percent data). In addition, when variances are not equal or if 
transformation failed to normalize the data, nonparametric statistics (Mann-Whitney rank 
sum test) were used. For all studies, the criterion for statistical significance was p<0.05. 
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RESULTS 
PAHs cause PLA� activation and 3B-AA release 
Little 3H-AA release was observed from unstimulated SMC (DMSO control group) or 
from cells exposed to the inactive P AH, AN; however, 1 -MA, caused significant, 
concentration-dependent release of 3H-AA (Figure 2A). TRI, PA, FA, but not CH, 
caused significant, concentration-dependent release of 3H-AA (Figure 2 B). FA and I ­
MF caused significant 3H-AA release; however, the response to 2,3-BF was not different 
from the vehicle-treated groups (Figure 2C). Pre-treatment with MAFP ( 1 0  µM), an 
inhibitor of group IV and VI PLA2 isoforms, attenuated approximately 60% of the 3H-AA 
release from cells treated with 1-MA, 1 -MF, FA, PA, and TRI; whereas pretreatment 
with BEL (7 .5 µM), an inhibitor of Group VI PLA2 isoforms induced approximately 20% 
inhibition in response to all PAHs (Figure 3). 
SMC demonstrate calcium-dependent and -independent PLA� activity 
To characterize further the PLA2 isoforms functioning in SMC, cell-free assays were 
performed. Cell-free PLA2 assays were performed using 14C-PC-AA/PC-AA or 14C-PC­
LA/ PC-LA as substrates in the absence of calcium. SMC displayed significant PLA2 
activity against both PC-AA and PC-LA, however, the activity -against PC-AA was 
greater. When PC-AA was used as a substrate the response was inhibited by MAFP but 
not BEL. However, when PC-LA was used as the substrate, both BEL and MAFP 
inhibited the effect (Figure 4). These data suggest the presence of Group IVy and VIJ3 
PLA2 isoforms in SMC. 
SMC exhibited significant PLA2 activity in the presence of calcium using both 
PC- 14C-AA and PC-14C-LA as substrates, however, the response was greater with PC-
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14C-AA than with PC- 14C-LA, suggesting that SMC contain PLA2 isoforms that are 
calcium-dependent, and either arachidonoyl selective/arachidonoyl non-selective. This 
calcium-dependent activity was inhibited in the presence of MAFP but not BEL (Figure 
5) suggesting that these cells demonstrate significant Group IVa and/or IVP PLA2 
activity. 
Treatment of cell lysates with different P AHs did not enhance PLA2 activity 
(Figure 6). PLA2 activity assayed on lysates treated with the active P AHs for 30 min. 
These data suggesting that P AHs might activate different PLA2 isoforms through 
membrane bound receptors. 
SMC express Group IVa, B, y, and Group VIB 
RT-PCR and Western analysis using PAR-treated SMC was performed to detect the 
expression of different PLA2 isoforms. mRNA and protein expression for both calcium­
independent and calcium-dependent enzymes was demonstrated by RT-PCR and Western 
analysis (Figure 7). SMC constitutively express group IV a, p, y, and VIP PLA2. 
Since the results of the cell-free assays, RT-PCR and Western analysis suggested that the 
SMC express all 4 isoforms of PLA2 , experiments were performed to evaluate whether 
incubation with P AHs would result in upregulation of these isoforms. Western blot 
analysis was performed using lysates from 2, 4, and 6 hrs-treated cells. 1 -MA, 1 -MF, FA 
and PA, but not TRI, AN, 2,3BF, CH, or vehicle caused a significant increase in 
expression of group VIP, IV a, and IVP (Figure 8). Figure 9 shows the increase in 
expression of Group Vly PLA2 after 4 hrs treatment with different PAHs. 1 -MA, PA, 1 -
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MF, and FA caused increase in expression of Vly PLA2, however TRI, AN, CH, and 2,3 
BF did not differ from control. 
PLA2 overexpression increased 3H-AA release in SMC 
Since the expression of PLA2 Groups VIJ3 and IVy were the most increased by treatment 
with PAHs, these proteins were overexpressed in SMC. Western analysis of the 
overexpressed cells were performed before conducting 3H-AA release experiments to 
ensure the increase expression. Figure 10 shows that both isoforms were increased in 
expression upon transfection. Group IVy and VIJ3 overexpression caused significant 
increase in 3H-AA release when compared to wild type cells upon exposure to PAHs 
(Figure 1 1  ). 
PAHs caused apoptosis in SMC 
The ability of different P AHs to phosphorylate F ADD was further determined. The SMC 
were treated with P AHs (30 µM) for 2 hrs, and total proteins were isolated. Equal 
amounts of proteins (40-60 µg) were subjected to immunoblot analysis (Figure 1 2). All 
active compounds, 1 -MA, PA, I -MF, FA, and TRI were able to activate and 
phosphorylate F ADD but not the inactive compounds or the vehicle. 
We evaluated caspase cleavage after 2, 4, and 6 hr of treatment with different 
PAHs. All five compounds (I -MA, I -MF, FA, TRI, and PA) that activate the PLA2/AA 
pathway and caused 3H-AA release were able to activate caspase-3 (Figure 13)  at 30 µM 
concentration after 6 hrs treatment. Whereas, 2,3BF, CH, AN, or vehicle, inactive 
compounds, did not cleave caspase-3 . No evidence of caspase-3 cleavage was observed 
after 2 or 4 hr treatment with P AHs. 
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Five out of eight compounds induced significant apoptosis as determined by 
Western analysis for the cleavage product of P ARP (Figure 14 ). I -MA, I -MF, TRI, FA, 
and PA, compounds that activated PLA2, also induced apoptosis. The three compounds, 
AN, CH, and 2,3BF, as well as the control that did not cause 3H-AA release, did not 
induce apoptosis. Cleavage was only detected after 8 hrs of treatment with I -MA and FA 
treated groups. The rest of the active compounds demonstrated P ARP cleavage after 12 
hrs of treatment. 
DISCUSSION 
This study is the first to provide strong evidence for the involvement of P AHs, which are 
present in high concentrations in CS as well as in industrial pollutants, in activation of the 
PLA2/ AA pathway and subsequent apoptosis of SMC. Five of the 8 compounds tested 
caused 3H-AA release in a concentration-dependent fashion. The 5 active compounds 
also induced apoptosis at a concentration that induced significant 3H-AA release. The 
onset of 3H-AA release proceed the onset of apoptosis by several hours. These results 
suggest a role for alteration in gene expression. In addition, specific PLA2 inhibitors that 
are selective for Group IV and VI enzymes inhibited 3H-AA release and attenuated the 
apoptotic effect suggest that P AHs induce SMC apoptosis by a mechanism that involves 
PLA2. 
The data suggest that activation of PLA2 and induction of apoptosis by P AHs 
requires discrete structural features. The major differences between 1-MA, 2-MA, and 
AN are that I -MA is a compound that contains a bay-like region on the molecule, 
whereas 2-MA and AN are linear compounds (Figure 1 ). These results are consistent 
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with previous studies by others that have demonstrated that bay- and bay-like regions are 
required for PAR-induced activation of c-jun-N-terminal kinase 1 9 • The results with CH; 
however, was inconsistent with this hypothesis since this compound has bay regions but 
was inactive. One possibility for this is that this compound is significantly bulkier than 
the other active compounds with bay- or bay-like regions. The existence of a discrete 
structural determinant for activity suggests that these compounds interact with a protein 
or proteins in the cell. Whether a ligand binds to a protein can depend on the size of the 
ligand. A large molecule may be too bulky to bind the active site of the protein, whereas 
a smaller molecule can. Another possible explanation for these results is that CH is 
significantly less water-soluble (0.002 mg/L) than the active compounds FA (0.26 mg/L) 
and PA (1 .6 mg/L). However, solubility cannot explain all the results. If so, it would be 
expected that a direct relationship would exist between water solubility and PLA2 
activation and this was not the case. For example, FA was significantly more active than 
PA in activating PLA2 and inducing apoptosis, but it was an order of magnitude less 
soluble than PA. Thus, it is likely that both molecular structure and solubility play 
important roles in the effects of P AHs on SMC cells PLA2 activation and apoptosis. 
Results from cell-free PLA2 assays suggested that SMC display significant PLA2 
activity against both PC-AA and PC-LA. The activity against PC-AA was greater in the 
presence than in absence of calcium, suggesting that SMC have significant calciwn­
dependent and -independent activities. Furthermore, the activity against PC-AA was 
significantly greater than that against PC-LA. These data indicate that SMC have both 
arachidonoyl-selective and arachidonoyl non-selective PLA2 isoforms. The results with 
RT-PCR and Western blotting confirm the results. The activity against PC-AA in the 
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presence of calcium was inhibited with MAFP but not BEL, excluding the po_ssibility that 
this assay was measuring group VI enzyme activity. The most likely PLA2s responsible 
for AA release under these conditions are Group IVP (a 1 1 4 kD protein) or Group IVa 
(85 kD). The cells also demonstrate Group VI(3 (85-88 kD protein). Under calcium-free 
condition, when PC-AA was used as a substrate the response was inhibited by MAFP but 
not BEL. However, when PC-LA was used as the substrate, both BEL and MAFP 
inhibited the effect. These data suggest the presence of Group IVy ( calcium-independent, 
and inhibited by MAFP), and VI(3 ( calcium-independent, and inhibited by MAFP and 
BEL) PLA2 isoforms in SMC. 
Treatment of the lysates directly with P AHs did not cause any increase in PLA2 
activity, suggesting that these compounds do not interact directly with PLA2 enzymes. It 
is possible that they act on the membrane by interacting with a receptor or with other 
downstream signaling protein in the cell. Indeed, a likely candidate is F ADD and the 
active P AHs were shown to induce phosphorylation of this protein. 
Since the results of the cell-free assays, RT-PCR, and Western analysis suggested 
that the SMC express all 4 isoforms of PLA2, Western blotting for the PAR-treated SMC 
for long term (6 hrs), caused significant induction of Group IVa, p, y, and VI(3 PLA2• 1 -
MA, PA, FA, 1 -MA, and TRI, and to a lesser extent the inactive linear compounds, 
caused significant increase in expression of all four enzymes after 6 hrs of treatment. The 
data suggest that P AHs might cause upregulation to different PLA2 isoforms that may be 
responsible for P AH-induced apoptosis of SMC. 
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Since inhibitor studies cannot definitively determine the specific PLA2s that are 
activated by select compounds, SMC were transfected with PLA2 isoforms that were the 
most strongly expressed by SMC after PAH treatment (Group IVy and Group Vlf3). 
W estem analysis for the overexpressed cells was performed to verify an increase in the 
expression of the protein in the overexpressed cells. Cells that overexpressd Group IVy 
and Vlf3 PLA2 release significantly more 3H-AA when stimulated with 1 -MA, FA, TRI, 
and PA when compared to wild type cells. In addition, cells overexpressing these 
enzymes were significantly more prone to apoptosis. The data suggest that both of these 
enzymes are responsible for P AH-induced AA release and subsequent apoptosis. We 
cannot, however, exclude the possibility that Group IV a and f3 are also involved in this 
effect since these enzymes are also targeted by MAFP. This possibility requires further 
investigation. 
SMC play an important role in the maintenance of fibrous plaque strength since 
they produce interstitial collagen that provides plaque tensile strength20. Activation of 
medial SMC that migrate into the intima to proliferate and produce extracellular matrix 
proteins is the key event in atherosclerosis2 1 . Recent studies provide compelling 
evidence that SMC apoptosis is an important mechanism of SMC loss, reduction of 
plaque tensile strength, and subsequent plaque rupture during atherosclerosis and acute 
myocardial infarction22. SMC are responsible for the production of interstitial collagen 
that is necessary for plaque stability. SMC apoptosis has been demonstrated in 
specimens from atherosclerotic and restenotic lesions of patients2 1,23 • In an in vitro study 
by Bennett and his colleagues, more apoptotic cells were observed in proliferating SMC 
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than non-proliferating SMC24• Another study showed a higher incidence of apoptosis in 
specimens from injured arteries in ballooned rat, mouse carotid, and rabbit iliac arteries 
than shown control. This apoptosis was demonstrated within 30 min, peaking after 7-1 5 
d and disappearing after re-endothelialization2 1 • Thus, SMC apoptosis is considered to be 
a rapid process after injury. Similar studies have been reported in other animal models 
and reviewed2 1 '23,25 • An increase in SMC apoptosis has also been demonstrated in 
cholesterol-fed rabbits and hyperlipidemic knockout mice2 1 • Furthermore, SMC cultured 
from atherosclerotic coronary lesions proliferate more slowly and undergo higher rates of 
apoptosis than SMC cultured from normal blood vessels. Thus several studies suggest 
that SMC proliferation is important for plaque stability and increase in SMC apoptosis is 
important in plaque instability. Since smooth muscle cell loss/injury is known to be 
important in the process of coronary artery disease and atherosclerotic disease involving 
other arteries as well, induction of SMC apoptosis by cigarette components may represent 
an important mechanism of smoking-induced augmentation of cardiovascular diseases. 
SUMMARY 
We investigated the effect of 8 different P AHs on SMC PLA2 activation and induction of 
apoptosis. Our data show that five of the 8 compounds tested cause 3H-AA release in a 
concentration-dependent fashion. The 5 active compounds also induce apoptosis at a 
concentration that induce significant 3H-AA release. In addition, specific PLA2 inhibitors 
that are selective for Group IV and VI enzymes inhibit 3H-AA release and attenuate' the 
apoptotic effect, suggesting that P AHs induce SMC apoptosis by a mechanism that 
involves PLA2. The data suggest that both discrete structure and solubility of P AHs play 
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an important role activation of PLA2 and induction of apoptosis in SMC. Results from 
cell-free PLA2 activity assays, RT-PCR, and Western blotting show that SMC express 4 
isoforms of PLA2, Group IVa., 13, y, and Group VIJ3 PLA2. Western blotting for the long 
term PAR-treated SMC (6 hrs), shows significant induction of all four enzymes, which 
suggests that P AHs may cause up-regulation to different PLA2 isoforms that may be 
responsible for PAR-induced apoptosis of SMC. Transfection of SMC PLA2 isoforms 
that are the most strongly expressed (Group IVy and Group VIJ3) cause a significant 
increase in 3H-AA when stimulated with active PAHs as compared to wild type cells. 
Our data suggest that both of these enzymes are responsible for P AH-induced AA release 
and subsequent apoptosis in SMC. Further investigation is required to test the possibility 
of Group IV a. and J3 involvement in this effect. 
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APPENDIX 
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1 -m ethylanthracene 
6 1 0 -4 8 -0 
1 -m e thy lfl u o rene  
1 7 3 0-3 7 -6 
F l u o ra n  th e n e  
2 0 6 -4 4 -0 
C h rysene 
2 I 8-0 1 -9 
CH 3 
A n th race n e  
P h e n a n t h r e n e  
8 5 -0  I - 8 
T riphenylene 
2 1 7 -5 9 -4 
2,3-benzofluorene 
92-24-0 
Figure 1 :  Structures of polycyclic aromatic hydrocarbons. Antrhracene (AN) has linear 
structures. 1 -metheylanthracene (1 -MA) and 1 -methylfluorene ( 1 -MF) have bay-like 
region formed by methyl group. Triphenylene (TRI), fluoranthene (FA), chrysene (CH), 
and phenantherene (PA) have bay-region. 2,3-benzofluorene (2,3 BF) has a truncated 
structure. 
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Figure 2. 3H-arachidonic acid {3H-AA) release from human aortic smooth muscle cells. 
Figure 2 A shows 3H-AA release induced by 1 -methylanthracene (1 -MA), but not by 
anthracene (AN). Cells were prelabeled with 3H-AA and stimulated for 1 h with vehicle 
or various concentrations of 1-MA or AN as described in Materials and Methods. 
Cumulative release of 3H-AA into the medium was measured by scintillation counting. 
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Figure 2. Continued. Figure 2 B shows 3H-arachidonic acid {3H-AA) release from human 
aortic smooth muscle cells induced by triphenllene (TRI) and phenanthrene (PA), but 
not chrysene (CH). Cells were prelabeled with H-AA and stimulated for 1 hour with 
various concentrations of FA, PA, CS or vehicle as described in Materials and Methods. 
Cumulative release of 3H-AA into the medium was measured by scintillation counting. 
*Significantly different from vehicle-treated control; n=6. 
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Figure 2. Continued. Figure 2 C shows 3H-arachidonic acid (3H-AA) release from human 
aortic smooth muscle cells induced by 1 -methylfluorene (1 -MF) and fluoranthene (FA), 
but not with 2,3-benzofluorene (2,3-BF). Cells were prelabeled with 3H-AA and 
stimulated for 1 h with various concentrations of 1 -MF, FA, 2,3-BF, or vehicle as 
described in Materials and Methods . Cumulative release of 3H-AA into the medium was 
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Figure 3. Inhibition of P AH-induced 3H-AA release by MAFP and BEL in smooth 
muscle cells (SMC). Pretreatment with MAFP (10 µM) or BEL (7.5 µM) for 30 min 
prior to treatment with different P AHs attenuated significantly 3H-AA release. The 
figure shows % inhibition caused by MAFP (10 µM) or BEL (7.5 µM). MAFP 
attenuated 3H-AA release by � 60% in 1-MA, FA, and PA-treated cells, while it caused < 
60% inhibition in 1-MF and TRI-treated cells. BEL induced approximately 20% 
inhibition in response to all P AHs. * denotes a statistically significant difference between 








Blank Protein+DMSO Protein+MAFP Protein+BEL 
Figure 4. SMC demonstrate significant Group IVy and VIP PLA2 activity. Cell-free 
PLA2 assays were performed using 
14C-PC-AA/PC-AA or 14C-PC-LA/ PC-LA as 
substrates in the absence of calcium. Lysate from SMC displayed significant PLA2 
activity against both PC-AA and PC-LA, however, the activity against PC-AA was 
greater. When PC-AA was used as a substrate the response was inhibited by MAFP but 
not BEL. However, when PC-LA was used as the substrate, both BEL and MAFP 
inhibited the effect. * denotes a statistically significant difference in PLA2 activity. #, 
denotes a statistically significant difference between control and treated groups 
(p < 0.05). 
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Blank Protein+DMSO Protein+MAFP Protein+BEL 
Figure 5. SMC demonstrate significant Group IVa and/or IVP PLA2 activity. Cell-free 
PLA2 assays were performed using 14C-PC-AA/PC-AA or 14C-PC-LA/ PC-LA as 
substrates in the presence of calcium. Significant PLA2 activity was seen against PC-AA 
and PC-LA, however, the activity against PC-AA was greater. MAFP, but not BEL, 
significantly inhibited PLA2 activity when PC-AA and PC-LA used as substrates. *, 
denotes a statistically significant difference in PLA2 activity. #, denotes a statistically 




2.5 * * * 
..... 
= .=: ..... 
2.0 .... e � 
< ]  
� 0 
r,.i I. 1.5 � c,_ 
c,_ � == 
$ 0 ..cl 0 
c,_ 
� 1 .0 r,.i 
0 = ..cl 
0.5 
Blank DMSO 1-MA 1-MF PA TRI 
Polycyclic Aromatic Hydrocarbons 
Figure 6. PAHs do not directly activate Groups IVy or VIJ3 PLA2 isoforms. Calcium­
independent cell free assays for Group IVy or VIJ3 were performed after treatment of cell 
lysates with 30 µM of PAHs or vehicle for 30 min. Exposure of lysates to 1 -MA, 1 -MF, 
PA, TRI, or vehicle did not alter activity of either enzyme. *, denotes a statistically 
significant difference between blank and protein (p < 0.05). 
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Figure 7. SMC express 4 different PLA2 isoforms: mRNA and protein expression for 
both calcium-dependent and calcium-independent enzymes were demonstrated by RT­
PCR and Western blotting. SMC constitutively express the Group VI J3 and Group 
IVa., J3, and y isoforms. n=3. Left panel shows Western blot analysis for Group N a, J3, 
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Figure 8. PAR-induced upregulation of different PLA2 isofonns. The effect of treatment 
of different P AHs on the expression of group VI f3 PLA2 (left panels A, B, and C) shows 
the effect of treatment after 2, 4, or 6 hrs respectively. Only FA and 1 -MA increased 
expression of Group VI f3 PLA2 after 4 hrs. However, after 6 hrs of treatment, all 
compounds increased protein expression, albeit, inactive compounds were less effective. 
Right panel A, B and C shows the difference in expression of group IV a and f3 PLA2 
isoforms after 2, 4 and 6 hr of treatment. No changes in expression of IV a (85 kD) were 
seen at 2 and 4 hrs, and only a slight increase in expression was seen at 6 hrs. However, 
expression of IV a was significantly increased after treatment with 1 -MA and FA after 4 
hrs and by all compounds (both active and inactive) by 6 hrs. A slight increase in VIf3 
expression was also seen at 6 hrs. n=3 . 
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Figure 9. PAR-induced upregulation of Group IVy PLA2 isoforms. The effect of 
treatment of different P AHs on the expression of Group IVy PLA2. The panel shows the 
effect of treatment after 4 hrs. FA, PA, 1-MF, and 1-MA increased expression of Group 




Figure 10. Western analysis of SMC overexpressing Group IVy and VIJ3 PLA2 • Cells 
were transfected with Gp IVy or VIJ3 and the lysates were collected as described 
previously. 8 % and 12% gels were run and the membranes were blotted using antibodies 
against different PLA2 isoforms. Panel A. shows increase in expression of group IVy 
compared to the wild type. Panel B shows increase in expression of group VIJ3 compared 
to the wild type. 
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Figure 1 1. Overexpression of lVy or VIJ3 PLA2 isoforms increases 3H-AA release in 
response to P AHs. Wild type SMC and SMC overexpressing either Group IVy or 
Group VIJ3 were prelabeled with 3H-AA for 24 hrs then exposed to different PAHs or 
vehicle for 1 hr. Release of 3H-AA into the medium was measured and the results were 
expressed as fold change in activity. Significant increases in activity for both isoforms 
were observed after treatments with 1-MA, FA, TRI, and PA. *, denotes a statistically 
significant difference between control and treated groups (p < 0.05). 
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Figure 12. Expression of FADD. The SMC were treated with P AHs (30 µM) for 3 hrs, 
and total proteins were isolated. Equal am_ounts of protein (40-60 µg) were subjected to 
immunoblot analysis. The figure shows F ADD phosphorylation with 1 -MA, 1-MF, FA, 
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Figure 13. Cleavage of caspase-3 induced by PAHs. SMC were treated with different 
PAHs (30 µM) for 2 hrs (panel A), 4 hrs (panel B) or 6 hrs (panel C), and total proteins 
isolated. Equal amounts of proteins ( 40.0 µg) were subjected to immunoblot analysis as 
described in Materials and Methods. No evidence of caspase-3 cleavage was detected 
after 2 or 4 hrs of treatment. After 6 hrs of treatment all of the active compounds (1-MA, 
1-MF, TRI, FA, and PA) activated caspase-3 while the inactive compounds as well as the 
vehicle control did not. n=3. 
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Figure 1 4. Apoptosis of SMC induced by different P AHs. Cells were exposed to 30 µM 
1 -MA, AN, 1 -MF, TRI, FA, PA, 2,3BF, CH, or vehicle for'·6 (panel A), 8 (panel B) or 12 
hrs (panel C) and apoptosis determined by detection of PARP cleavage (~ 85 kD) as 
described in Materials and Methods. n=3. Only I -MA and FA showed PARP cleavage at 
8hrs. While all active compounds induced P ARP cleavage by 12 hrs. No 85 kD 
fragment was detected from cells treated with AN, 2,3 BF, or CH at any time. n=3 
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